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ABSTRACT: Despite the high diversity of histamine H3 receptor (H3R) antagonist/inverse agonist structures, partial or full
H3R agonists have typically been imidazole derivatives. An in-house screening campaign intriguingly afforded the non-imidazole
4-(3-azetidin-1-yl)pyrimidin-2-amine 11b as a partial H3R agonist. Here, the design, synthesis, and structure−activity
relationships of 11b analogues are described. This series yields several non-imidazole full agonists with potencies varying with
the alkyl substitution pattern on the basic amine following the in vitro evaluation of H3R agonism using a cyclic adenosine
monophosphate response element-luciferase reporter gene assay. The key compound VUF16839 (14d) combines nanomolar
on-target activity (pKi = 8.5, pEC50 = 9.5) with weak activity on cytochrome P450 enzymes and good metabolic stability. The
proposed H3R binding mode of 14d indicates key interactions similar to those attained by histamine. In vivo evaluation of 14d
in a social recognition test in mice revealed an amnesic effect at 5 mg/kg intraperitoneally. The excellent in vitro and in vivo
pharmacological profiles and the non-imidazole structure of 14d make it a promising tool compound in H3R research.
■ INTRODUCTION
The four histamine receptors (H1R, H2R, H3R, H4R) belong to
class A of the G protein-coupled receptor (GPCR) family.1
The histamine H3 receptor (H3R) was discovered in 1983 by
Arrang et al.2 and regulates the release of several neuro-
transmitters such as histamine (1), acetylcholine, serotonin,
noradrenaline, and dopamine, as both auto- and hetero-
receptor.1 Due to its expression in the cortex, striatum, and
hippocampus, H3R regulates several physiological processes
such as sleep−wake regulation, cognition, and food intake.1,3
During the early years of discovery of H3R ligands, the
natural ligand histamine served as an initial structure for drug
design, leading to a plethora of imidazole-containing ligands.
However, imidazole-containing ligands are associated with
drug−drug interactions due to the propensity for cytochrome
P450 (CYP) inhibition and having poor brain penetration.4,5
Therefore, research toward therapeutically relevant H3R
antagonists focused on druglike non-imidazole structures,6,7
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and these efforts have led to numerous clinical candidates for
different indications connected to central nervous system
diseases, for example, Alzheimer′s disease, attention deficit
hyperactivity disorders, sleep disorders, schizophrenia, obesity,
epilepsy, and neuropathic pain and narcolepsy.8,9 For the latter
condition, the H3R ligand pitolisant (Wakix) was approved by
the European Medicines Agency in 201610 and, most recently,
by the Food and Drug Administration in 2019.11
In sharp contrast, developing non-imidazole H3R agonists
has not been very successful. The best agonists contain an
imidazole ring12−23 and, compared to the endogenous ligand
histamine (1), these derivatives show similar [e.g., imbutamine
(2)] or significantly higher affinity (pKi) and/or functional
activity (pEC50) on H3R [e.g., imetit (3), methimepip (4), and
(1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane
(5)] (Figure 1A). Imidazole-containing agonists have shown
some potential application in different therapeutic areas, such
as mechanical nociception,23 obesity, and diabetes mellitus
(diet-induced obesity mice test)24 and stress (rodent-intruder
mice test).21 Some data also support the hypothesis of
cardioprotective effect of H3R receptor activation.
25,26
However, it is fair to say that imidazole-containing agonists
may suffer from the same imidazole-related drawbacks that
were associated with the first generation of imidazole-
containing H3R antagonists (vide supra). Future studies on
the pharmacological and therapeutic roles of H3R agonists can
therefore be helped by having non-imidazole H3R agonists
available.
A very limited number of non-imidazole agonists have been
published to date (Figure 1B). VUF8430 (6) was designed as
an H4R agonist based on the H2R agonist dimaprit and shows
micromolar affinity and full H3R agonism as well.
27 The
histamine analogues amthamine (7a) and amselamine (7b)
were identified as H2R agonists, but both show weak H3R
agonist activity in an electrically stimulated guinea-pig jejunum
model.28,29 Three pentacyclic spiroindolinone derivatives were
isolated from Penicillium waksmanii, of which PF1270A (8)
shows the best affinity for H3R and moderate functional H3R
activity in a guanosine 5′-O-[γ-thio]triphosphate (GTPγS)
accumulation assay.30 ZEL-H16 (9) has been reported to have
nanomolar binding affinity to the H3R, partial H3R agonism in
forskolin-stimulated cAMP accumulation and ERK1/2 signal-
ing assays, and full H3R agonism in a guinea-pig ileum
contraction assay.31 Finally, a compound set with 94 examples
in four compound families with either a β-lactam or a
pyrrolidinone central core without basic amino moiety was
published recently and surprisingly included compounds with
nanomolar functional H3R agonist activities (e.g., compound
10).32 The fungal isolates and the multicomponent reaction
product 10 are large and complex molecules, which are difficult
to align with known H3R pharmacophores or H3R binding
modes for agonists and antagonists. We therefore started a
search for novel high-affinity non-imidazole H3R full agonists
with simpler structures to generate fundamental knowledge on
ligand recognition and signaling of the H3R.
■ RESULTS
Design. During an in-house compound screen aimed at
identifying agonist activities in a set of ligands using a H3R-
driven reporter gene assay in HEK293T cells, diaminopyr-
Figure 1. (A) Representative imidazole H3R agonists. Activities are extracted from Igel et al.,
33 Govoni et al.,18 and Kazuta et al.12 (B) Published
non-imidazole H3R (partial) agonists.
27−32 Unless mentioned otherwise, compounds were tested on the human receptor. α, intrinsic activity
compared to histamine; β-gal, cyclic adenosine monophosphate (cAMP) response element (CRE)-β-galactosidase reporter gene assay; cAMP,
forskolin-stimulated cAMP accumulation assay.
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Figure 2. (A) Initial functional data of compounds 11b and 11i compared to histamine, as obtained by ligand-induced activation of hH3R
expressed on HEK293T cells measured by the CRE-luc reporter gene assay. Shown is a representative graph of at least three experiments performed
in triplicate. Data are mean ± standard deviation (S.D.). (B) Structures of 11b and 11i, the closest relevant structure (14a) resulting from a
subsequent extensive patent search and the compound set designed for the current study.
Scheme 1. Syntheses Routes for Final Compoundsa
aReagents and conditions: (i) POCl3, 110 °C, 3 h, 26−52%; (ii) N,N-diisopropylethylamine (DIPEA), dioxane or N-methyl-2-pyrrolidone (NMP),
microwave (μW), 120−150 °C, 0.5−2 h, 27−50% (a, b) or 35−71% (c, d, f, two steps from benzhydryl deprotection); (iii) HCl, dichloromethane
(DCM), MeOH, room temperature (rt) to 50 °C, 3 h to overnight, 10% to quant.; (iv) aldehyde/ketone, AcOH, NaHB(OAc)3, DCM, MeOH, rt,
3 h to overnight, 16−44%; or 1,4-diiodobutane, K2CO3, MeCN, reflux, 16 h, 9%; (v) N,N-dimethylazetidin-3-amine dihydrochloride, DIPEA,
dioxane, μW, 150 °C, 30 min, 65%; (vi) di-tert-butyl dicarbonate, triethylamine (TEA), tetrahydrofuran (THF), rt, overnight, 63%; (vii) NaH, R2I,
THF, 0 °C to rt, overnight, 28−58%; (viii) H2, Pd/C, MeOH, EtOH, rt to 60 °C, 1 h to overnight, not purified and used crude.
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imidine 11b emerged as a H3R partial agonist hit (α = 0.7),
while its close derivative 11i showed only weak agonist activity
(α = 0.4) (Figure 2A). Interestingly, a set of four
diaminopyrimidine compounds has been tested before by
others on H3R en route to imbutamine (2) analogues, but the
majority of these diaminopyrimidines were rather inactive and,
where applicable, all were shown to be antagonists/inverse
agonists.34 Intrigued by the agonist activity of the diaminopyr-
imidine 11b and recognizing its core as a thoroughly explored
heterocycle in the H4R area,
35 we decided to perform an in-
depth patent search on this scaffold in an effort to capture the
full array of industrial contributions. This resulted in the
identification of 14a (Figure 2B) as the closest derivative with
data associated with H3R (Figure 2B).
36 Remarkably, 14a was
claimed as a H3R agonist by Abbott, although its actual
synthesis was not included and only the potential synthetic
route was described.36 In the same patent, 25 related examples
have been prepared, and partial agonism at the human H3R is
reported.36
Based on 11b and 14a, we designed a focused series of
compounds to explore the H3R affinity and activity in the
chemical space between 14a and 11b (Figure 2B). The design
strategy targets four series with iPr, Et, Me, or H as the R1
group at position 6 (11−14). These R1 groups were combined
with different substituents on the basic amino groups (R2 and
R3). Beyond the evident H (a) and Me (b) substituents,
dimethyl derivatives (i) were synthesized due to the potential
functional switch that appears to reside in the cases of 11b and
11i. Based on the initial results of the designed compound set
(vide infra), the R1 = H series was extended with elongated (d
and f), branched (e, g, h), and disubstituted (j, k) amino
derivatives. This second design iteration was also inspired by
previous work from our labs on the imidazole-containing
agonist imbutamine (2), which harbors a functional switch on
the basic amine.18 Beyond 14a, some exact compounds from
this designed set are known but none in a context of H3R. That
is, 11a, 11b, and 12b have been claimed as H4R ligands,
37,38
while 12i, 13i, 14i, 14j, and 14k were offered in chemical
catalogs (April 2019) without any synthesis description and
analytical or pharmacological data.
Chemistry. The designed compound set shown in Figure
2B was synthesized as outlined in Scheme 1. The key step of
the synthetic route was a nucleophilic aromatic substitution on
the appropriate aromatic cores with aminoazetidine moieties
(step ii). The 4-chloro-2-aminopyrimidines were commercially
available (19 and 20) or were synthesized (17 and 18) from
the appropriate pyrimidin-4(3H)-one derivatives (15 and 16)
with POCl3. The R
2 = H or Me derivatives of the Boc-
protected 3-aminoazetidines (28a and 28b) were commercially
available, while the R2 = Et, nPr, and nBu derivatives were
synthesized. These intermediates were built from benzhydryl-
protected 3-aminoazetidine (25) with Boc protection of the
Table 1. Pharmacological Evaluation of Designed Compound Set
compound R1 R2 R3 pKi
c pEC50
d α
histamine 7.9 ± 0.2 8.6 ± 0.0 1.0 ± 0.0
11a iPr H H 6.7 ± 0.0 7.1 ± 0.1 0.7 ± 0.0
11b iPr Me H 7.0 ± 0.0 7.9 ± 0.4 0.7 ± 0.1
11c iPr Et H 7.0 ± 0.1 6.8 ± 0.3 0.3 ± 0.1
11i iPr Me Me 6.9 ± 0.0 7.0 ± 0.2 0.4 ± 0.0
12a Et H H 7.1 ± 0.0 7.5 ± 0.0 0.9 ± 0.0
12b Et Me H 7.3 ± 0.1 7.6 ± 0.0 0.8 ± 0.0
12c Et Et H 6.9 ± 0.1 7.5 ± 0.1 0.9 ± 0.0
12i Et Me Me 6.6 ± 0.2 7.2 ± 0.1 0.8 ± 0.0
13a Me H H 7.3 ± 0.1 7.8 ± 0.0 0.9 ± 0.0
13bb Me Me H 7.5 ± 0.1 8.0 ± 0.0 0.8 ± 0.1
13c Me Et H 7.1 ± 0.1 7.9 ± 0.0 1.0 ± 0.0
13i Me Me Me 6.5 ± 0.2 7.4 ± 0.0 0.9 ± 0.1
14aa H H H 7.8 ± 0.1 8.3 ± 0.0 1.1 ± 0.0
14ba H Me H 8.2 ± 0.1 8.9 ± 0.1 1.1 ± 0.1
14ca H Et H 8.0 ± 0.1 9.2 ± 0.0 1.0 ± 0.1
14da H nPr H 8.5 ± 0.1 9.5 ± 0.1 1.2 ± 0.1
14ea H iPr H 7.4 ± 0.1 8.5 ± 0.1 1.2 ± 0.1
14fa H nBu H 7.8 ± 0.1 9.1 ± 0.3 1.2 ± 0.0
14ga H rac-sBu H 7.9 ± 0.2 8.7 ± 0.1 1.1 ± 0.0
14ha H iBu H 7.4 ± 0.2 8.3 ± 0.0 1.1 ± 0.0
14ia H Me Me 7.3 ± 0.1 8.4 ± 0.1 1.0 ± 0.1
14ja H Et Et 7.2 ± 0.1 8.1 ± 0.1 1.2 ± 0.1
14ka H -(CH2)4- 7.4 ± 0.1 8.1 ± 0.0 1.3 ± 0.2
aMeasured as fumarate salt. bMeasured as dihydrochloride salt. cAffinity values (pKi) were determined by [
3H]NAMH displacement assay on
hH3R expressed on HEK293T cell homogenates.
dPotency (pEC50) and intrinsic activity (α) were determined by ligand induced activation of
hH3R expressed on HEK293T cells as measured by a CRE-luciferase reporter gene assay. Data are mean ± standard error of the mean (S.E.M.) of
at least three experiments performed in triplicate.
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primary amino group to give 26, followed by alkylation with
the corresponding iodoalkyl reagents resulting in the
orthogonally protected intermediates (27c, 27d, 27f) and the
removal of the benzhydryl group with hydrogenation. The
resulting mixtures of unprotected azetidine intermediate and
diphenylmethane were used directly for the ensuing
nucleophilic substitution with 17−20. The key nucleophilic
aromatic substitution of the appropriate Boc-protected
intermediates was performed in a microwave at 120−150 °C
to give 21−24. This was followed by the deprotection under
acidic condition to afford the majority of monosubstituted (R2
= H or linear alkyl, R3 = H) products 11−14. Although the
Boc protection was necessary at the precursor stage to avoid
overalkylation in the case of linear alkyl derivatives, over-
alkylation was not a problem in the case of the branched-alkyl
derivatives as a result of steric hindrance. Therefore, the
branched-alkyl derivatives 14e, g, and h as well as the
dialkylated derivatives 12i, 13i, 14i, and 14j were synthesized
from 14a with a reductive amination. Last, 11i was synthesized
directly from 17 and N,N-dimethylazetidin-3-amine with a
nucleophilic substitution, while the pyrrolidine ring of 14k was
obtained from 1,4-diiodobutane and 14a.
Pharmacological Evaluation. The synthesized com-
pound set was tested for its activity at the human H3R
transiently expressed in HEK293T cells. Binding affinity (Ki)
was evaluated using a [3H]NAMH displacement assay, while
potency (EC50) and intrinsic activity (α) were determined as
the H3R-mediated inhibition of forskolin-induced CRE-driven
luciferase reporter gene activity with histamine as the control
(Table 1 and Figure 3). During the first iteration, the isopropyl
group of 11b was gradually decreased in size to give 11−14,
which were all combined with small-size R2/R3 amino
substituents (a, b, c, i). The affinities of the unsubstituted
derivatives (14) stand out especially within the monomethy-
lated (b) and monoethylated series (c), with both 14b and 14c
exceeding the affinity of histamine. Although monomethylated
(b) derivatives generally show the highest affinities in each R1
subseries 11−14, the most notable variation was observed in
the case of the monoethylated series c, with affinities of Me/
Et/iPr derivatives 11c, 12c, and 13c being considerably
reduced compared with that of 14c (Figure 3A). A more
indicative trend was observed in the case of the functional
results of this c series. Compound 14c has a higher potency
than 14b and produces the same intrinsic activity (α) as
histamine but with higher potency (EC50), while 12c and 13c
show >1 log unit weaker EC50 albeit with maintained full
agonism (α ∼ 1.0). Interestingly, isopropyl substitution on the
R1 position (11c) turns this full agonism to partial agonism (α
= 0.3) (Figure 3B). A similar trend was observed in the other
three series, with the pyrimidine derivatives bearing R1 = H
(14a−c and 14i) reaching or exceeding the affinity (Ki) and
potency (EC50) of histamine, while any alkyl substituent at
position 6 (R1) on the pyrimidine leads to inferior results. The
intrinsic activity (α) indicates full or almost full agonism (α ≥
0.8) in the methyl (12a, 12b, 12i) and ethyl (13a, 13b, 13i)
series, while it drops to partial agonism in the isopropyl series
(11a, 11b, 11i) (Table 1).
Due to the better results of the pyrimidines lacking an R1
substituent (14), in a subsequent iteration the amine NHR2
substituent was replaced with longer linear groups (14d, 14f),
branched groups (14e, 14g, 14h), or dialkylamino (14j, 14k)
moieties. Representative curves illustrate the structure−activity
relationship (SAR) (Figure 3C) and SFR (Figure 3D) of this
series. The nPr derivative 14d shows the highest affinity (pKi =
8.5) from all linear monoalkyl substituents. Although both
shorter and longer R2 moieties resulted in lower binding
affinities (e.g., 14c: pKi = 8.0 or 14f: pKi = 7.8), all derivatives
remained in the same affinity range (Figure 3C). The
branched-alkyl moieties as well as the dialkylated derivatives
display loss of affinity (compare, e.g., 14d vs 14e, or 14b vs
Figure 3. Representative structure−affinity relationship (A, C) and structure−function relationship (SFR) (B, D) effects selected from Table 1. (A,
B) Different R1 substituents with R2 = Et and R3 = H (11c, 12c, 13c, 14c), (C, D) Different R2 and R3 substituents with R1 = H (14b, 14d, 14e,
14f, 14i). Shown is a representative graph of at least three experiments performed in triplicate. Data are mean ± S.D.
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14i). The potencies (EC50) show almost the same trends as
observed for the affinities (Figure 3D). Highly noteworthy, the
potency of 14d (pEC50 = 9.5) is almost a log unit higher than
that of histamine (pEC50 = 8.6), while chain shortening (e.g.,
14b, 14c), chain lengthening (14f), chain branching (e.g.,
14e), or dialkylation (e.g., 14i) results in lower potencies. In
contrast to the observed differences in affinity and potency, the
intrinsic activities indicate that all derivatives of 14 remain full
agonists (α ≥ 1.0) (Table 1). A combination of highest affinity
(pKi = 8.5), highest potency (pEC50 = 9.5), and full agonism
resides in 14d. The potential aggregation of GPCR ligands
might cause nonspecific effect on the receptor activity,39 but
nephelometry revealed no microprecipitation of 14d up to 100
mM concentration (Figure S1) and underscores the high
aqueous (aq) solubility of 14d (soluble up to at least 100 mM
in 50 mM Tris−HCl, pH 7.4). All this led to identification of
14d as a key compound (VUF16839) in this study.
Computational Studies on 14d. A combination of
molecular docking and molecular dynamics (MD) simulations
was used to evaluate the potential binding mode of the key
compound 14d and to compare it to the binding mode of the
endogenous ligand histamine. A homology model of H3R
based on the available crystal structure of H1R was used (see
the Experimental section). This model was validated by its
ability to retrospectively discriminate between known H3R
fragmentlike ligands and true inactives.40 Histamine was
docked in the receptor model using PLANTS 1.1 (Figure
4A). The best-scored docking pose showing interactions with
both D1143.32 and E2065.461 (residues known to be involved in
H3R ligand binding
40−45) was selected. During 100 ns of
molecular dynamics (MD) simulations, histamine is able to
maintain stable interactions with residues D1143.32 and
E2065.461 as well as with Y3746.51 (Figure 4B,E). Using similar
procedures, compound 14d was also docked into the same
homology model using PLANTS 1.1 (Figure 4A), and the
best-scored docking results show similar interactions of 14d
with D1143.32 and E2065.461. The basic amine of 14d forms an
ionic interaction with the negatively charged side chain of
D1143.32, and the amino group in the pyrimidine ring makes a
hydrogen bond with E2065.461. Different docking poses
maintain these key interactions but show a different position-
ing of the linear nPr moiety at the R2 position: toward the
extracellular surface of the receptor or toward the intracellular
side (Figure S2A,B, respectively). MD simulations of the two
alternative models were performed (Movies 1 and 2,
Supporting Information). The model in which the nPr group
of 14d is directed toward the intracellular half of the receptor
was not stable along 100 ns of MD simulations (Figure S2D,
Movie 2, Supporting Information), while the model where the
nPr group of 14d is pointing toward the extracellular vestibule
remained stable throughout the entire simulation time (Figure
S2C and Movie 1, Supporting Information). This binding
mode is shown in Figure 4D, and the interactions that
remained stable during the simulations are depicted in Figure
4C and the interaction fingerprints (IFPs) in Figure 4E. It can
be concluded that the non-imidazole H3R ligand 14d exerts its
unusual agonist H3R activity by showing a similar pharmaco-
phore as the endogenous H3R ligand. That is, it may achieve its
Figure 4. Predicted binding mode of 14d. (A) Overview of the H3R homology model based on the H1R crystal structure (PDB ID: 3RZE).
46 The
experimentally validated binding mode of histamine (magenta) is shown in more detail in (B), and the predicted binding mode of 14d (green) is
schematically represented in (C) and shown in more detail in (D). Interaction fingerprint representations of histamine and compound 14d are
shown in (E), where a one represents the presence of an interaction according to the color coding: blue for apolar, olive green for face-to-face
aromatic, green for edge-to-face aromatic, red for protein hydrogen bond donor, purple for ligand hydrogen bond donor, gray for ligand-negative
charge, and orange for protein-negative charge.
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agonist activity by forming similar interactions with the same
residues as histamine.
Pharmacological and Pharmacokinetic Characteriza-
tion of 14d. Functional characterization of key compound
14d in a direct G protein activation assay, that is, the [35S]-
GTPγS accumulation assay on hH3R expressing cell homoge-
nates (Figure 5A), results in potent but partial agonism (pEC50
= 8.4 ± 0.3, α = 0.5 ± 0.05) compared with histamine (pEC50
= 7.2 ± 0.3, α = 1.0 ± 0.0).
Due to the high homology of the hH3R with hH4R (43% full
sequence identity, 58% predicted transmembrane region
identity),47 several, mainly imidazole-containing, hH3R ligands
are known to possess high affinity to hH4R as well,
33,44
although there are examples of imidazole-containing H3R
agonists with high H3R/H4R selectivity as well (e.g., 4 and
5).12,33 Therefore, 14d was tested for its H3R/H4R selectivity.
The pyrimidine shows only marginal selectivity with respect to
binding hH3R or hH4R (hH3R pKi = 8.5 ± 0.1 vs hH4R pKi =
8.1 ± 0.0), but encouragingly a 10-fold selectivity in potency is
observed in favor of the hH3R (hH3R pEC50 = 9.5 ± 0.1 vs
hH4R pEC50 = 8.5 ± 0.2) with full agonism on hH4R (α = 1.1
± 0.1) in a CRE-luc reporter gene assay. Moreover, 14d does
not activate the H1R and H2R up to 10 μM (Figure S3).
Equally encouragingly, the binding affinity of 14d is
increased for mH3R (pKi = 9.0 ± 0.1) compared with hH3R,
while for mH4R, the pKi value is decreased to 7.8 ± 0.0, thus
yielding a substantial H3R/H4R binding selectivity for mouse
receptors. Compound 14d was also functionally evaluated as
an agonist on the mH3R and mH4R using the CRE-luciferase
reporter gene assay. In these experiments, 14d displays a 10-
fold selectivity in potency (mH3R pEC50 = 10.0 ± 0.1 vs mH4R
pEC50 = 9.0 ± 0.1), while it acts as a full agonist on both
murine receptors (mH3R α = 1.2 ± 0.1 and mH4R α = 1.1 ±
0.1) (Figure 5B,C).
The metabolic stability of 14d was determined in vitro by
incubation with rodent liver microsomes (Table 2). The
pharmacokinetic properties for mouse [t1/2 = 130.8 min; Clint =
20.7 mL/(min*kg)] indicate more than 2 times slower
elimination compared with the reference control verapamil.48
For rats, this difference between 14d and verapamil is even
more pronounced.
The imidazole ring is known to generally be able to interact
with CYP enzymes via coordination of the imidazole with the
prosthetic heme iron, which can cause unwanted drug−drug
interaction.49 Since the 2-aminopyrimidine core contains a
pattern of adjacent nitrogen atoms, we measured its propensity
for CYP inhibition. Compound 14d shows only weak activity
on three key CYP enzymes (Figure S4) with IC50 values for
binding to CYP3A4, CYP2C9, and CYP2D6 all being larger
than 25 μM.
Effect of 14d on Social Recognition in Mice. Given the
notion that CNS penetration of H3R agonists,
1,5 including 14d,
is not evident, we evaluated the in vivo CNS effects of 14d in a
standard paradigm for H3R action. It is well known that
histamine, acting in different brain sites, is an important
regulator of memory consolidation and retrieval in various
learning paradigms, including the social recognition test.50,51
We used this behavioral paradigm to investigate the H3R-
related CNS activity of compound 14d in vivo. The social
recognition memory investigates the ability to remember the
identity of a conspecific, which is crucial to the building of
social relationships and survival. Twenty-four hours after
animals’ habituation to the apparatus, the subject mouse was
placed in an open-field arena with an empty cage and another
one containing a juvenile mouse. Mice tend to spend more
time in the proximity of the cage containing the juvenile mouse
than the empty one, offering an indication of sociability. One
hour later, the experimental mouse was placed again in the
same arena, but this time one cage contained the familiar
mouse and the second one a novel juvenile mouse. The
exploration times of the familiar and the novel mouse were
recorded separately. Compound 14d at a dose of 5 mg/kg or
vehicle was given intraperitoneally (i.p.) 30 min before the
training session (Figure 6A). Compound 14d did not affect
animals’ sociability as revealed by the longer time that they
spent exploring the cage containing the social stimulus
compared with the empty cage (Figure S5). In this respect,
mice treated with compound 14d behaved like controls.
During the test session, control mice recognized the familiar
juvenile, since they spent more time exploring the novel one.
Conversely, mice treated with 14d did not discriminate
between the novel and the familiar mouse (Figure 6B). This
result clearly suggests a social memory impairment, further
confirmed by the negative discrimination index (DI) calculated
for the group of animals receiving injections of 14d (Figure
6C).
Figure 5. (A) Dose-dependent Gαi activation by 14d and histamine as measured by [
35S]GTPγS accumulation on HEK293T cell homogenates
expressing the hH3R. (B, C) Dose−response curves of 14d and histamine for ligand-induced activation of mH3R (B) and mH4R (C) expressed on
HEK293T cells as measured by the CRE-luciferase reporter gene assay. Representative graphs of at least three experiments performed in triplicate
are shown. Data are mean ± S.D.
Table 2. Pharmacokinetic Properties of 14d and the
Reference Drug Verapamil
rat liver microsomes mouse liver microsomes
compound
t1/2
(min)
Clint
[mL/(min*kg)]
t1/2
(min)
Clint
[mL/(min*kg)]
14d 239.0 7.9 130.8 20.7
verapamil 50.9 37.3 57.3 47.3
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■ DISCUSSION AND CONCLUSIONS
We present 2-aminopyrimidine derivatives with an alkylated 3-
amino-azetidine moiety showing low nanomolar affinities for
the H3R. Based on the non-imidazole partial agonist 11b
identified as an in-house hit, a 23-membered compound set
was synthesized and tested on H3R. The reduction of the
substituent size at position 6 of the pyrimidine ring (R1)
improved both affinity (pKi) and potency (pEC50) on hH3R.
Each member of the extended R1 = H series (14) shows full
agonism in a CRE-luciferase reporter gene assay, with three
derivatives (14b−d) improving upon the endogenous ligand
histamine, combining full H3R agonism with high (sub)-
nanomolar potencies. Most notably, the key non-imidazole
H3R agonist 14d (VUF16839) combines high affinity to the
H3R (pKi = 8.5) with full agonism at the H3R and a
subnanomolar potency (pEC50 = 9.5) in a CRE-luciferase
reporter gene assay. However, 14d acts as a partial agonist in
an [35S]GTPγS accumulation assay with a 13-fold lower
potency as compared with the more downstream CRE-
luciferase reporter gene assay, which is most likely the
consequence of signal amplification as suggested by a 25-fold
higher potency of the full agonist histamine in the CRE-
luciferase reporter gene assay as compared with an [35S]GTPγS
accumulation assay.
From the recent development of numerous series of H4R
antagonists, it is known that 2-aminopyrimidine is a privileged
scaffold for H4R antagonism.
35 As such, it is not surprising that
14d also binds with relatively high affinity to the H4R (pKi =
8.1). It acts as an agonist at H4R, but it is 10-fold less potent
than at H3R, while 14d is not active at H1R and H2R.
The subnanomolar potency of the non-imidazole compound
14d as an agonist at H3R is remarkable, as so far only a few
low-potency and/or complex non-imidazole ligands have been
reported as agonists at H3R.
27−32 Indeed, replacements of the
imidazole ring while maintaining agonism have so far yielded
little success. To illustrate, several imbutamine (2) analogues
in which the imidazole moiety was replaced with an
aminopyrimidine, aminopyridine or aminotriazole ring studied
were not effective as H3R agonists.
34 Comparing the activities
of the aminopyrimidine analog of 2 with 14d, the effective
activation of H3R by 14d suggests a very important role of its
azetidine side chain. Molecular docking combined with MD
studies affords a predicted binding mode (Figure 4) in which
14d interacts with the same key amino acids (D1143.32,
E2065.461, Y3746.51) as histamine (1) (Figure 4E), suggesting
that the 2-aminopyrimidine moiety mimics the imidazole ring.
The computational studies also suggest that the azetidine side
chain makes an ionic interaction with the same amino acid
(D1143.32) as the amine group in the ethylamine side chain of
histamine. Clearly, both 14d and histamine are able to interact
with the same key amino acids of H3R, despite the fact that the
binding modes of 14d and histamine do not substantially
overlap.
The alkyl substitution of the basic amino moiety of 2 was
studied previously in our group,18 and subtle differences in
alkyl substituents on the basic amine strongly influence the
functional activity of such imbutamine analogs. Based on this
SAR, we hypothesize that the basic amine of the 2-
aminopyrimidine compound series 11−14 might be a
functional “hot spot” as well. In the case of the R1 = iPr
series (11), this appears to partially pan out as the chain
elongation and dialkylation show moderate drops in intrinsic
activity (α) (compare 11b vs 11c and 11i in Table 1).
However, such a trend was not observed within the other series
12−14 (Table 1 and Figure 3D).
The analysis of additional properties for key compound 14d
underscores its suitability for in vivo characterization in mice.
That is, mouse potency data (mH3R: pEC50 = 10.0, mH4R:
pEC50 = 9.0) and in vitro elimination parameters in mouse
[t1/2 = 130.8 min; Clint = 20.7 mL/(min*kg)] all bode well.
The inhibition of CYP enzymes is a general issue of imidazole-
containing ligands.49 Although the diaminopyrimidine core
might conceivably also be prone to CYP inhibition, 14d only
weakly (IC50 > 25 μM) interacts with selected key CYP
enzymes (CYP3A4, CYP2D6, CYP2C9).
Poor brain penetration is a known problem of some
imidazole-containing ligands,5 limiting their potential admin-
istration routes in CNS-related experiments. As indicated by
the effects in the in vivo social memory test, the 2-
aminopyrimidine 14d (5 mg/kg i.p.) is clearly penetrating
the CNS. Histamine is a known modulator of different types of
memory.3,52 H3R antagonists, such as thioperamide, improve
short-term memory, while H3R agonists such as immepip (4)
cause amnesia in the social recognition test.51 The results
shown here confirm and expand these observations, since a
memory impairment was observed also for systemic treatment
with compound 14d in the same paradigm (Figure 6). It
should be noted that H3R activation affects the circadian
rhythm by increasing slow wave sleep and dose-dependently
attenuates ciproxifan-induced waking effects.53 Also, H3R
agonists reduce stress-induced behavior in preclinical models.54
These observations suggest that H3R activation may affect
exploratory activity, which could negatively impact arousal and
cognition. We did not specifically measure 14d-induced
alterations of the sleep−wake cycle; however, 14d-associated
social memory impairment does not seem to be related to
Figure 6. Compound 14d impairs social recognition in mice. (A)
Schematic drawings showing the sequence of procedures and
treatment administrations. (B) Results are calculated as means of
individual percentage of time spent exploring familiar (white
columns) and novel (black columns) social stimuli. ***P < 0.001
vs the respective familiar subject [two-way analysis of variance
(ANOVA) and Bonferroni’s MCT]. (C) Discrimination index
calculated according to the formula tN − tF/tN + tF. **P < 0.01
vs vehicle (unpaired t-test). Shown are means ± S.E.M. of 10−11
animals per experimental group.
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sedative effects, as there were no statistically significant
differences between the control group and 14d-treated mice
in exploration time of the cage in the presence or absence of
the social stimulus (during training: vehicle = 144.0 ± 60.0 s;
14d = 136.2 ± 44.1 s; during test: vehicle = 150.5 ± 42.4 s;
14d = 148.3 ± 69.4 s). Moreover, based on the mH3R/mH4R
selectivity profile of 14d (vide supra), available literature on
H4R expression, H4R agonist actions in the CNS, and the
behavioral profile of H4R-deficient mice excluding a relevant
role of this receptor on the histaminergic modulation of
memory processing, it is highly unlikely that the in vivo
amnesic effects of 14d are confounded by its H4R activity.
55,56
Indeed, the amnesic effects of 14d are consistent with the
memory impairments observed following treatment with
different H3R agonists [imetit (3) and (R)-α-methylhistamine]
in the object recognition and passive avoidance tests in rats.57
To conclude, in this study, 2-aminopyrimidine derivatives
with an alkylated 3-amino-azetidine side chain are presented as
highly potent, non-imidazole agonists for the H3R. The key n-
propyl derivative (14d, VUF16839) shows attractive in vitro
pharmacological properties on human H3R (pKi = 8.5, pEC50 =
9.5, α ≥ 1.0 in a CRE-luciferase reporter gene assay with a 10-
fold lower potency at H4R) and mouse H3R (pKi = 9.0, pEC50
= 10.0, with a >10-fold lower potency at mH4R). It exerts
reasonable metabolic stability in rodent liver microsomes and
weak activity on CYP enzymes. Moreover, 14d causes amnesic
effects in social recognition tests in mice at 5 mg/kg, which is
in line with the reported memory loss after administration of
other H3R agonists.
51,57 The observed in vivo H3R effects also
indicate appreciable brain penetration of 14d. Compound 14d
can serve as a useful tool compound for fundamental studies
concerning H3R, given its excellent affinity and potency, H3R
agonism, and effective brain penetration.
■ EXPERIMENTAL SECTION
Pharmacology and ADME. Materials. [3H]NAMH (specific
activity: 79.7 Ci/mmol) and [3H]histamine (specific activity: 17.5 Ci/
mmol) were purchased from PerkinElmer (Groningen, the Nether-
lands). Human embryonic kidney 293T cells (HEK293T cells) were
obtained from ATCC. Ketoconazole, quinidine, sulfaphenazole, and
verapamil were obtained from Sigma-Aldrich (St. Louis, MO).
Cell Culture and Transfection. HEK293T cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum and 1% penicillin and 1% streptomycin. Two
million cells per 10 cm2 dishes were plated 24 h prior to transfection.
Cells were transfected using the polyethylenimine (PEI) method.58
For radioligand displacement assays, HEK293T cells were transfected
with 2500 ng of complementary DNA (cDNA) encoding the hH3R
(genbank: AF140538), mH3R (genbank: NM_133849.3), hH4R
(genbank: AY136745), or mH4R (genbank: NM_153087.2) and
2500 ng of empty plasmid pcDEF3. The DNA/PEI mixture (ratio
1:4) was incubated for 20 min at 22 °C before addition to the cells.
Preparation of Cell Homogenates. Cell homogenates expressing
the hH3R were harvested 48 h after transfection as reported
previously.59
Radioligand Displacement Assays. [3H]NAMH and [3H]-
histamine displacement assays were performed in a binding buffer
(50 mM Tris−HCl pH 7.4, 25 °C) by coincubation of 2 nM
[3H]NAMH or 10 nM [3H]histamine, increasing concentrations of
unlabeled ligand and cell homogenates expressing the hH3R/mH3R or
hH4R, respectively. For mH4R displacement, similar studies were
performed but with 30 nM [3H]histamine. The assay mixture was
incubated for 2 h at 25 °C before rapid filtration over a 0.5% PEI-
coated GF/C filter with a PerkinElmer filtermate harvester. The filter
plate was dried, and 300 min after 25 μL of Microsint O was added,
filter-bound radioactivity was measured with a Microbeta scintillation
counter (PerkinElmer).
[35S]GTPγS Accumulation Assay. [35S]GTPγS accumulation
experiments on hH3R were performed as described previously.
60
Reporter Gene Assay. HEK293T cells were transfected in
suspension with cDNA encoding hH3R, mH3R, hH4R, mH4R, H1R
(1000 ng) or H2R (2500 ng), CRE-luciferase (2500 ng) or NFAT-
luciferase (2000 ng) for H1R, and empty pcDEF3 plasmid, and 50.000
cells per well were plated on a poly-L-lysine-coated white 96-well plate
and grown for an additional 24 h. Cells were stimulated with
increasing ligand concentrations for H3R and H4R in the presence of 1
μM forskolin at 37 °C and 5% CO2. After 6 h, the medium was
aspirated and 25 μL of luciferase assay reagent [0.83 mM adenosine
5′-triphosphate, 0.83 mM D-luciferin, 18.7 mM MgCl2, 0.78 μM
Na2PO4, 38.9 mM Tris−HCl (pH 7.8), 0.39% glycerol, 0.03% Triton-
X-100, and 2.6 μM dithiothreitol] was added to each well. After 30
min of incubation at 37 °C, luminescence was measured with a
Mithras plate reader (Berthold, Germany).
Data Analysis. Data were analyzed using GraphPad prism 7.02
(GraphPad Software Inc., San Diego). Shown data are mean ± S.E.M.
of three individual experiments performed in triplicate unless stated
otherwise. Competition binding curves were fitted to a one-site
binding model. Obtained IC50 values were converted into pKi values
using the Cheng−Prusoff equation.61 Dose−response curves were
fitted using nonlinear regression.
Metabolic Stability. The pharmacokinetic parameters of 14d and
the reference drug verapamil were estimated by using rat liver
microsomes (RLMs) or mouse liver microsomes (MLMs) obtained
from Sigma-Aldrich (St. Louis, MO). The tested compounds (50
μM) were incubated in the presence of microsomes (1 mg/mL) for 5,
15, 30, and 45 min in 10 mM Tris−HCl buffer (pH = 7.4) at 37 °C.
Cold methanol with an internal standard (IS) was added to terminate
each reaction. Next, the reaction mixtures were centrifuged at 14 500
rpm. The disappearance of the tested compounds in time was
calculated by the UPLC/MS Waters ACQUITY TQD system with a
TQ Detector (Waters, Milford). The course of the reaction was
followed by using the analyte/IS peak height ratio values. For the
determination of the t1/2 value, the slope of linear regression from log
concentration remaining versus time relationships (−k) was used
according to Obach48 (eq 1)
= −t
k
0.683
1/2 (1)
Conversion of t1/2 to intrinsic clearance Clint [in units of mL/
(min*kg)] was done by using eq 2
= × ×
×
t
Cl
0.693 mL incubation
mg microsomes
mg microsomes
g liver
g liver
kg b.w.
int
1/2
(2)
where 45 mg of microsomal protein per gram of liver tissue (g liver)
and 87 g of liver per kilogram of body weight (kg b.w.) were applied
to calculate Clint in mice, whereas 61 mg of microsomal protein per g
liver and 45 g of liver per kg b.w. were applied to calculate Clint in rats,
according to Huang et al.62 and Smith et al.63
Effect on CYP. Luminescent CYP3A4, CYP2D6, and CYP2C9
P450-Glo assays and protocols were obtained from Promega
(Madison, WI). Compound 14d was tested in triplicate at the final
concentrations in range from 0.01 to 25 μM. The luminescent signal
was measured by using a microplate reader EnSpire PerkinElmer
(Waltham, MA).
Social Recognition Test. Male C57Bl6 mice (8−9 weeks old)
behavior was assessed in a test apparatus comprising an open-field
plexiglass arena (45 × 25 cm2 and 20 cm high) placed in a sound-
attenuated room. The assay paradigm comprises three sessions. In the
first session, mice were placed in the arena containing two empty
pencil-wire cups placed on opposing sides and left free to explore for
10 min. Twenty-four hours after this session, a juvenile mouse
(stimulus, 4−5 weeks old), which had no prior contact with the
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subject mice, was placed under one of the wire cups while the other
cup remained empty. The subject mouse was then placed in the arena
and was left free to explore for 10 min. During the third session,
performed 1 h later, the same stimulus animal was again placed under
the wire cup and a novel unfamiliar juvenile mouse was placed under
the opposing cup. Subject mice were then placed again in the arena
and tested for discrimination between novel and familiar mice in a 10
min session. Each mouse was subjected to the procedure separately,
and care was taken to remove any olfactory/taste cues by cleaning
carefully the arena and wire cups between trials. The positions of the
social stimuli (empty × social; familiar × novel) were counter-
balanced across subjects and trials to prevent bias from place
preference. Stimulus mice were habituated to remain under the wire
cups several days before behavioral testing. Vehicle or 14d (5 mg/kg)
was injected systemically (i.p.) 30 min before the second session. The
animal’s behavior during all sessions was videotaped, and the time
spent actively exploring the stimuli was analyzed by experienced
observers unaware of the experimental groups. Exploration was
defined as direct snout-to-cup contact, and the time spent climbing on
the cups was not considered. Data are expressed as a percentage of
time spent exploring each cup (social × nonsocial during the second
session or familiar × novel during the third session), and statistical
significance was determined by the two-way ANOVA followed by
Bonferroni’s test. We also determined a sociability index, calculated
according to the formula [time exploring social cup (tS) − time
exploring nonsocial cup (tNS)]/[total exploration time (tS + tNS)],
and a discrimination index (DI), which was calculated according to
the formula [time exploring the novel mouse (tN) − time exploring
the familiar mouse (tS)]/[total exploration time (tN + tF)], both
analyzed using unpaired t-tests.
Computational Studies. Residue Numbering. Residue number-
ing is displayed throughout the manuscript as absolute sequence
numbers and with generic numbering from GPCRdb64 also in
superscript, in which the first number denotes the helix, 1−8, and the
second number denotes the residue position relative to the most-
conserved residue, defined as number 50, in a gapped sequence
alignment.
Homology Modeling. A three-dimensional model of the H3R was
constructed on Modeller v.9.1565 based on the crystal structure of
H1R (PDB ID: 3RZE).
46 The sequence of H3R was obtained from
UniProt66 and aligned to the crystal structure sequence based on the
structure-based alignment of GPCRdb. An optimal structure was
selected based on its ability to retrospectively discriminate between
known H3R fragmentlike ligands and true inactives as described
elsewhere.40
Docking. A conformational library of all of the compounds was
obtained with Corina v3.4967 and protonated in ChemAxon
Calculator.68 The most energetically favorable conformations were
docked using PLANTS v1.1.69 Hundred docking poses were
generated per conformation and postprocessed with interaction
fingerprints (IFPs) inferred from OpenEye’s OChem 1.3 library.70,71
IFPs are bit vectors that are switched off (0) or on (1) depending on
the occurrence of predefined intermolecular interactions [apolar, face-
to-face, and face-to-edge aromatic interactions, hydrogen bonds
(acceptor or donor), and ionic interactions (cationic or anionic)].
Molecular Dynamics Simulations and Analysis. Ligands were
parametrized using the AM1-BCC charges in Antechamber.72 The
selected models were energy minimized to optimize protein−ligand
interactions and used to run membrane-embedded MD simulations in
GROMACS.73 Each system was simulated for 100 ns after an
equilibration of 5 ns, with the parameters and conditions described
elsewhere.74 Potential energy, root-mean-square deviation, root-mean-
square fluctuation, and dihedrals of the simulations were analyzed
with GROMACS tools, and residue interactions were analyzed with
IFPs.
Nephelometry. In transparent flat-bottom 96-well plates, 14d was
placed at different concentrations in triplicate (10−1, 10−1.5, 10−2,
10−2.5, 10−3, 10−3.5, 10−4, and 10−4.5 M) in Tris−HCl binding buffer
(50 mM Tris−HCl, pH 7.4) at least 1 h before the measurement. A
Kaolin dispersion was used as a positive control75 in each plate at
different concentrations (10−2.5, 10−3, 10−3.5, 10−4, 10−4.5, 10−5, and
10−5.5 M) under the same conditions as with compound 14d.
Nephelometry measurements were performed with a NEPHELO star
Plus (BMG Labtech, Germany) with the following settings: one cycle,
measurement start time 0.1 s, measurement interval time 0.1 s, laser
intensity 80%, beam focus 2.0 mm, orbital shaking mode at 200 rpm
with an additional shaking time of 10 s before each cycle. Results were
analyzed using Matlab R2014A (8.3.0.532) software, plotting all
available data points and plotting mean and standard deviation values
in a line chart compared to the Kaolin control. The linear fit (R2) of
the Kaolin control was above 0.985 in all cases.
Chemistry. General Information. Chemicals and solvents were
obtained from commercial suppliers and were used without further
purification. THF was dried by passing through the PureSolv solvent
purification system by Inert. All reactions were carried out under an
inert N2 atmosphere. Hydrogenation experiments were performed
with routine batch technology or the H-cube Mini Plus flow reactor.
Microwave reactions were performed with the Biotage Initiator
microwave system. Thin-layer chromatography analyses were
performed with Merck F254 alumina silica plates using UV
visualization or staining. Column purifications were carried out
automatically using Biotage Isolera or Teledyne Isco CombiFlash
equipment using Silicycle Ultra Pure silica gel. Melting point (mp) for
final compounds was determined using a Büchi M-565 melting point
apparatus at a rate of 1 °C/min. NMR spectra were recorded on a
Bruker 250, 300, 500, or 600 MHz spectrometer. Chemical shifts are
reported in ppm (δ), and the residual solvent was used as the internal
standard (δ 1H NMR: CDCl3 7.26; CD3OD 4.87; D2O 4.79;
13C
NMR: CDCl3 77.16; CD3OD 49.00). Data are reported as follows:
chemical shift, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet;
p, pentet; sext, sextet; hept, heptet; br, broad signal; m, multiplet; app,
apparent), coupling constant(s) (Hz), and integration. High-
resolution mass spectra (HRMS) were recorded on a Bruker
microTOF mass spectrometer using electrospray ionization in the
positive ion mode. Analytical high-performance liquid chromatog-
raphy (HPLC)-mass spectrometry (MS) analyses were conducted
using a Shimadzu LC-20AD liquid chromatograph pump system
connected to a Shimadzu SPDM20A diode array detector with MS
detection using a Shimadzu HPLC-MS 2010EV mass spectrometer.
The column used is an Xbridge C18 5 mm column (50 mm × 4.6
mm). Acidic mode: solvent B (MeCN/0.1% formic acid) and solvent
A (water/0.1% formic acid), flow rate of 1.0 mL/min with a run time
of 8 min. For compounds whose retention time (tR) was less than 1.5
min with the acidic solvent system, a basic solvent system was used.
Basic mode: solvent B (MeCN/10% buffer), solvent A (water/10%
buffer). The buffer is a 0.4% (w/v) NH4HCO3 solution in water,
adjusted to pH 8.0 with NH4OH. The analysis was conducted using a
flow rate of 1.0 mL/min with a total run time of 8 min. Gradient
settings (basic and acidic system): start 5% B, linear gradient to 90%
B in 4.5 min, then isocratic for 1.5 min at 90% B, then linear gradient
to 5% B in 0.5 min, then isocratic for 1.5 min at 5% B. All compounds
(except 14c and 14f) have a purity of ≥95% calculated as the
percentage peak area of the target compound by UV detection at 254
nm using the analytical HPLC-MS method listed above. Yields
reported are not optimized. The compounds described in Table 1
were checked for the presence of pan assay interference compounds
(PAINS) substructures as described by Baell and Holloway,76 and no
PAINS substructures were identified.
4-(3-Aminoazetidin-1-yl)-6-isopropylpyrimidin-2-amine (11a).
To a solution of carbamate 21a (351 mg, 1.14 mmol) in MeOH
(20 mL) was added aq HCl (37%, 0.35 mL, 4.23 mmol). The reaction
mixture was stirred at rt overnight. The solvents were removed under
reduced pressure. The residue was dissolved in DCM/MeOH (10:1,
10 mL). The pH was adjusted to above 10 with NH3 solution (7 N)
in MeOH. The suspension was filtered. The solvents were removed
under reduced pressure. The crude product was dissolved in hot
EtOH (5 mL), and after addition of EtOAc (5 mL), a precipitate
formed. The formed solid was collected by filtration, washed, and
dried in vacuo. Purification by flash chromatography (DCM/MeOH/
TEA 100:0:0−90:9:1) gave the title compound as a white solid (53
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mg, 22%). mp: 157.0−157.6 °C. 1H NMR (600 MHz, CD3OD) δ
5.58 (s, 1H), 4.25 (t, J = 8.1 Hz, 2H), 3.95−3.85 (m, 1H), 3.72 (dd, J
= 9.0, 5.2 Hz, 2H), 2.64 (hept, J = 7.0 Hz, 1H), 1.21 (d, J = 6.9 Hz,
6H). 13C NMR (151 MHz, CD3OD) δ 175.4, 165.7, 164.0, 89.8, 59.9,
44.1, 36.6, 22.0. HPLC-MS (basic mode): tR = 2.6 min, purity: >99%,
[M + H]+: 208. HR-MS [M + H]+ calcd for C10H18N5
+: 208.1557,
found 208.1564.
4-Isopropyl-6-(3-(methylamino)azetidin-1-yl)pyrimidin-2-amine
(11b). To a solution of carbamate 21b (96 mg, 0.30 mmol) in DCM
(5 mL) was added HCl in dioxane (4 N, 1.0 mL, 4.0 mmol). The
reaction mixture was stirred for 3 h at rt. The reaction mixture was
diluted with satd. aq Na2CO3 (10 mL) and extracted with DCM (3 ×
5 mL). The combined organic phases were dried over Na2SO4,
filtered, and concentrated in vacuo. Purification by flash chromatog-
raphy (DCM/MeOH/TEA 100:0:0−90:9:1) gave the title compound
as a white solid (45 mg, 68%). mp: 81.8−82.4 °C. 1H NMR (500
MHz, CDCl3) δ 5.47 (s, 1H), 5.05 (br, 2H), 4.23−4.15 (m, 2H),
3.76−3.63 (m, 3H), 2.65 (hept, J = 6.9 Hz, 1H), 2.42 (s, 3H), 1.19
(d, J = 6.9 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 173.8, 164.4,
162.0, 89.1, 56.7, 50.5, 35.4, 33.3, 21.6. HPLC-MS (basic mode): tR =
3.1 min, purity: 97.3%, [M + H]+: 222. HR-MS [M + H]+ calcd for
C11H20N5
+: 222.1713, found 222.1718.
4-(3-(Ethylamino)azetidin-1-yl)-6-isopropylpyrimidin-2-amine
(11c). To a solution of carbamate 21c (79 mg, 0.24 mmol) in MeOH
(4 mL) was added aq HCl (37%, 0.19 mL, 2.29 mmol). The reaction
mixture was stirred at rt overnight. The solvents were removed under
reduced pressure. The residue was dissolved in DCM/MeOH (4:1, 8
mL). The pH was adjusted to above 10 with NH3 solution (7 N) in
MeOH. The inorganic salts were filtered off and washed with DCM/
MeOH (4:1, 12 mL). The filtrate was concentrated under reduced
pressure. The crude product was dissolved in hot EtOH (1 mL), and
after addition of EtOAc (5 mL), a precipitate formed. The formed
solid was collected by filtration, washed, and dried in vacuo. The title
compound was obtained as a white solid (25 mg, 45%). mp: 226.2−
227.3 °C. 1H NMR (600 MHz, CD3OD) δ 5.97 (s, 1H), 4.63 (br,
1H), 4.57 (br, 1H), 4.46 (br, 1H), 4.37 (br, 1H), 4.35−4.27 (m, 1H),
3.13 (q, J = 7.2 Hz, 2H), 2.87 (hept, J = 6.8 Hz, 1H), 1.38 (t, J = 7.2
Hz, 3H), 1.32 (d, J = 6.9 Hz, 6H). 13C NMR (151 MHz, CD3OD) δ
164.2, 163.6, 157.0, 91.5, 54.8, 54.4, 48.2, 42.4, 33.3, 20.9, 11.7.
HPLC-MS (basic mode): tR = 3.2 min, purity: >99%, [M + H]
+: 236.
HR-MS [M + H]+ calcd for C12H22N5
+: 236.1870, found 236.1868.
4-(3-(Dimethylamino)azetidin-1-yl)-6-isopropylpyrimidin-2-
amine (11i). A microwave vial charged with amine 17 (248 mg, 1.44
mmol), N,N-dimethylazetidin-3-amine dihydrochloride (250 mg, 1.44
mmol), DIPEA (0.76 mL, 4.33 mmol), and dioxane (10 mL) was
heated for 30 min at 150 °C under microwave irradiation. The
reaction mixture was diluted with water (20 mL) and extracted with
DCM (3 × 20 mL). The combined organic phases were dried over
Na2SO4, filtered, and concentrated in vacuo. Purification by flash
chromatography (DCM/MeOH/TEA 100:0:0−90:9:1) gave the title
compound as a white solid (220 mg, 65%). mp: 123.6−123.8 °C. 1H
NMR (500 MHz, CDCl3) δ 5.49 (s, 1H), 4.87 (br, 2H), 4.04 (t, J =
7.8 Hz, 2H), 3.94−3.81 (m, 2H), 3.21 (p, J = 5.6 Hz, 1H), 2.65 (hept,
J = 6.8 Hz, 1H), 2.20 (s, 6H), 1.20 (d, J = 6.8 Hz, 6H). 13C NMR
(126 MHz, CDCl3) δ 174.0, 164.6, 162.1, 89.1, 56.2, 53.9, 41.8, 35.5,
21.7. HPLC-MS (basic mode): tR = 3.4 min, purity: 97.8%, [M + H]
+:
236. HR-MS [M + H]+ calcd for C12H22N5
+: 236.1870, found
236.1878.
4-(3-Aminoazetidin-1-yl)-6-ethylpyrimidin-2-amine (12a). To a
solution of carbamate 22a (250 mg, 0.85 mmol) in MeOH (20 mL)
was added aq HCl (37%, 0.21 mL, 2.54 mmol). The reaction mixture
was stirred at rt overnight. The solvents were removed under reduced
pressure. The residue was dissolved in DCM/MeOH (10:1, 40 mL).
The pH was adjusted to above 10 with NH3 solution (7 N) in MeOH.
The suspension was filtered. The solvents were removed under
reduced pressure. The crude product was dissolved in hot EtOH (5
mL), and after addition of EtOAc (15 mL), a precipitate formed. The
formed solid was collected by filtration, washed, and dried in vacuo.
Dissolving in H2O (5 mL) and freeze-drying gave the title compound
as a white fluffy solid (95 mg, 58%). mp: 224.7−225.9 °C. 1H NMR
(600 MHz, CD3OD) δ 5.83 (s, 1H), 4.51−4.37 (m, 2H), 4.16−4.02
(m, 3H), 2.50 (q, J = 7.6 Hz, 2H), 1.18 (t, J = 7.6 Hz, 3H). 13C NMR
(151 MHz, CD3OD) δ 164.1, 160.2, 157.4, 92.7, 56.5, 42.6, 27.1,
12.2. HPLC-MS (basic mode): tR = 2.3 min, purity: >99%, [M + H]
+:
194. HR-MS [M + H]+ calcd for C9H16N5
+: 194.1400, found
194.1410.
4-Ethyl-6-(3-(methylamino)azetidin-1-yl)pyrimidin-2-amine
(12b). To a solution of carbamate 22b (450 mg, 1.46 mmol) in
MeOH (20 mL) was added aq HCl (37%, 0.36 mL, 4.35 mmol). The
reaction mixture was stirred at rt overnight. The solvents were
removed under reduced pressure. The residue was dissolved in DCM/
MeOH (10:1, 20 mL). The pH was adjusted to above 10 with NH3
solution (7 N) in MeOH. The suspension was filtered. The solvents
were removed under reduced pressure. The crude product was
dissolved in hot EtOH (5 mL), and after addition of EtOAc (15 mL),
a precipitate formed. The formed solid was collected by filtration,
washed, and dried in vacuo. Dissolving in H2O (5 mL) and freeze-
drying gave the title compound as a white fluffy solid (150 mg, 50%).
mp: 202.8−203.3 °C. 1H NMR (600 MHz, CD3OD) δ 5.89 (s, 1H),
4.51−4.39 (m, 2H), 4.11 (dd, J = 10.1, 3.5 Hz, 2H), 3.96 (br, 1H),
2.58 (q, J = 7.9 Hz, 2H), 2.55 (s, 3H), 1.27 (t, J = 7.6 Hz, 3H). 13C
NMR (151 MHz, CD3OD) δ 164.1, 160.4, 157.6, 92.6, 55.9, 50.4,
32.3, 27.2, 12.2. HPLC-MS (basic mode): tR = 2.6 min, purity: >99%,
[M + H]+: 208. HR-MS [M + H]+ calcd for C10H18N5
+: 208.1557,
found 208.1566.
4-Ethyl-6-(3-(ethylamino)azetidin-1-yl)pyrimidin-2-amine (12c).
To a solution of carbamate 22c (117 mg, 0.36 mmol) in MeOH (4
mL) was added aq HCl (37%, 0.30 mL, 3.62 mmol). The reaction
mixture was stirred at rt overnight. The solvents were removed under
reduced pressure. The residue was dissolved in DCM/MeOH (9:1, 3
mL). The pH was adjusted to above 10 with NH3 solution (7 N) in
MeOH. The inorganic salts were filtered off and washed with DCM/
MeOH (9:1, 8 mL). The filtrate was concentrated under reduced
pressure. The crude product was dissolved in hot EtOH (1.5 mL),
and after addition of EtOAc (7 mL), a precipitate formed. The
formed solid was collected by filtration, washed, and dried in vacuo.
The title compound was obtained as a white solid (8 mg, 10%). mp:
236.6−236.9 °C. 1H NMR (600 MHz, CD3OD) δ 5.99 (s, 1H), 4.60
(br, 2H), 4.48−4.26 (m, 3H), 3.13 (q, J = 7.3 Hz, 2H), 2.64 (q, J =
7.6 Hz, 2H), 1.38 (t, J = 7.2 Hz, 3H), 1.31 (t, J = 7.6 Hz, 3H). 13C
NMR (151 MHz, CD3OD) δ 164.2, 159.8, 157.0, 92.8, 54.8, 54.4,
48.2, 42.4, 26.8, 12.0, 11.7. HPLC-MS (basic mode): tR = 2.9 min,
purity: >99%, [M + H]+: 222. HR-MS [M + H]+ calcd for C11H20N5
+:
222.1713, found 222.1703.
4-(3-(Dimethylamino)azetidin-1-yl-6-ethyl)pyrimidin-2-amine
(12i). To a solution of amine 12b (110 mg, 0.53 mmol) in MeOH (5
mL) were added formaline (37%, 47 μL, 0.64 mmol) and AcOH (30
μL, 0.53 mmol). After 10 min of stirring at rt, NaBH(OAc)3 (169 mg,
0.80 mmol) was added, and the resulting mixture was stirred for 3 h at
rt. The reaction mixture was quenched with 5 M aq NaOH (two
drops). The solvents were removed under reduced pressure. The
residue was dissolved in DCM/MeOH (4:1, 8 mL). The pH was
adjusted to above 10 with NH3 solution (7 N) in MeOH. The
inorganic salts were filtered and washed with DCM/MeOH (4:1, 12
mL). The filtrate was concentrated under reduced pressure. The
crude product was purified by flash chromatography (DCM/MeOH/
TEA 100:0:0−90:9:1). The selected fractions were collected, and the
solvents were removed under reduced pressure. The residue was
dissolved in DCM (5 mL) and washed with satd. aq Na2CO3 (10
mL). The aqueous phase was extracted with DCM (2 × 5 mL). The
combined organic phases were dried over Na2SO4, filtered, and
concentrated in vacuo. The residue was dissolved in MeOH (10 mL)
and washed with c-hexane (20 mL). The c-hexane layer was extracted
with MeOH (2 × 5 mL). The combined MeOH layers were
concentrated in vacuo to give the title compound as a white solid (34
mg, 29%). mp: 128.7−128.9 °C. 1H NMR (600 MHz, CD3OD) δ
5.63 (s, 1H), 4.15−4.05 (m, 2H), 3.85 (dd, J = 9.0, 5.1 Hz, 2H),
3.30−3.23 (m, 1H), 2.43 (q, J = 7.6 Hz, 2H), 2.23 (s, 6H), 1.20 (t, J =
7.6 Hz, 3H). 13C NMR (151 MHz, CD3OD) δ 171.6, 165.6, 164.0,
91.3, 57.4, 54.7, 41.9, 31.2, 13.4. HPLC-MS (basic mode): tR = 2.9
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min, purity: >99%, [M + H]+: 222. HR-MS [M + H]+ calcd for
C11H20N5
+: 222.1713, found 222.1705.
4-(3-Aminoazetidin-1-yl)-6-methylpyrimidin-2-amine (13a). To
a solution of carbamate 23a (723 mg, 2.59 mmol) in MeOH (25 mL)
was added aq HCl (37%, 3.26 mL, 39.4 mmol). The reaction mixture
was stirred at rt overnight. The solvents were removed under reduced
pressure. The residue was dissolved in DCM/MeOH (10:1, 40 mL).
The pH was adjusted to above 10 with NH3 solution (7 N) in MeOH.
The suspension was filtered. The solvents were removed under
reduced pressure. The crude product was recrystallized from EtOH.
The crystals were collected by filtration, washed, and dried in vacuo.
Dissolving in H2O (5 mL) and freeze-drying gave the title compound
as a white fluffy solid (189 mg, 43%). mp: 204.7−206.5 °C. 1H NMR
(600 MHz, CD3OD) δ 5.89 (s, 1H), 4.50−4.43 (m, 2H), 4.17−4.11
(m, 1H), 4.06 (dd, J = 10.6, 4.8 Hz, 2H), 2.28 (s, 3H). 13C NMR
(151 MHz, CD3OD) δ 164.0, 157.8, 155.9, 94.0, 57.4, 43.0, 19.3.
HPLC-MS (basic mode): tR = 2.0 min, purity: >99%, [M + H]
+: 180.
HR-MS [M + H]+ calcd for C8H14N5
+: 180.1244, found 180.1244.
4-Methyl-6-(3-(methylamino)azetidin-1-yl)pyrimidin-2-amine
Dihydrochloride (13b). To a solution of carbamate 23b (193 mg,
0.66 mmol) in dioxane (2 mL) was added HCl in dioxane (4 N, 2.0
mL, 8.0 mmol). The reaction mixture was stirred at rt overnight. The
solvents were removed under reduced pressure. The title compound
was obtained as an off-white solid (176 mg, quant.). mp: 220.1−220.5
°C. 1H NMR (600 MHz, CD3OD/D2O) δ 6.01 (s, 1H), 4.69−4.56
(m, 2H), 4.46−4.29 (m, 3H), 2.82 (s, 3H), 2.36 (s, 3H). 13C NMR
(151 MHz, CD3OD/D2O) δ 163.4, 156.2, 154.8, 94.3, 54.1, 53.7,
49.3, 31.6, 18.8. HPLC-MS (basic mode): tR = 2.3 min, purity: >99%,
[M + H]+: 194. HR-MS [M + H]+ calcd for C9H16N5
+: 194.1400,
found 194.1401.
4-(3-(Ethylamino)azetidin-1-yl)-6-methylpyrimidin-2-amine
(13c). To a solution of carbamate 23c (124 mg, 0.40 mmol) in
MeOH (4 mL) was added aq HCl (37%, 0.33 mL, 3.99 mmol). The
reaction mixture was stirred for 3 h at rt. The solvents were removed
under reduced pressure. The residue was dissolved in DCM/MeOH
(9:1, 8 mL). The pH was adjusted to above 10 with NH3 solution (7
N) in MeOH. The inorganic salts were filtered off and washed with
DCM/MeOH (4:1, 12 mL). The filtrate was concentrated under
reduced pressure. The title compound was obtained as a white solid
(70 mg, 84%). mp: 218.1−219.2 °C. 1H NMR (600 MHz, CD3OD) δ
5.85 (s, 1H), 4.44−4.34 (m, 2H), 4.03 (dd, J = 10.6, 4.8 Hz, 2H),
3.98−3.91 (m, 1H), 2.78 (q, J = 7.2 Hz, 2H), 2.26 (s, 3H), 1.20 (t, J =
7.2 Hz, 3H). 13C NMR (151 MHz, CD3OD) δ 164.0, 158.2, 156.4,
93.9, 56.6, 48.9, 42.2, 19.6, 13.8. HPLC-MS (basic mode): tR = 2.7
min, purity: 96.4%, [M + H]+: 208. HR-MS [M + H]+ calcd for
C10H18N5
+: 208.1557, found 208.1549.
4-(3-(Dimethylamino)azetidin-1-yl-6-methyl)pyrimidin-2-amine
(13i). Free base 4-methyl-6-(3-(methylamino)azetidin-1-yl)pyrimidin-
2-amine (160 mg, 0.83 mmol) was obtained from 13b by
neutralization with NH3 solution (7 N) in MeOH and filtration of
the inorganic salt, followed by evaporation of the solvent. The residue
was dissolved in MeOH (5 mL). To this were added formaline (37%,
74 μL, 0.99 mmol) and AcOH (47 μL, 0.83 mmol). After 10 min of
stirring at rt, NaBH(OAc)3 (263 mg, 1.24 mmol) was added, and the
resulting mixture was stirred for 3 h at rt. The reaction mixture was
quenched with 5 M aq NaOH (two drops). The solvents were
removed under reduced pressure. The residue was dissolved in DCM/
MeOH (4:1, 8 mL). The pH was adjusted to above 10 with NH3
solution (7 N) in MeOH. The inorganic salts were filtered off and
washed with DCM/MeOH (4:1, 12 mL). The filtrate was
concentrated under reduced pressure. The crude product was purified
by flash chromatography (DCM/MeOH/TEA 100:0:0−90:9:1). The
selected fractions were collected, and the solvents were removed
under reduced pressure. The residue was dissolved in DCM (5 mL)
and washed with satd. aq Na2CO3 (10 mL). The aqueous phase was
extracted with DCM (2 × 5 mL). The combined organic phases were
dried over Na2SO4, filtered, and concentrated in vacuo. The residue
was dissolved in MeOH (10 mL) and washed with c-hexane (20 mL).
The c-hexane layer was extracted with MeOH (2 × 5 mL). The
combined MeOH layers were concentrated in vacuo to give the title
compound as a white solid (65 mg, 38%). mp: 171.5−172.7 °C. 1H
NMR (600 MHz, CD3OD) δ 5.63 (app d, J = 3.2 Hz, 1H), 4.15−4.04
(m, 2H), 3.91−3.80 (m, 2H), 3.30−3.23 (m, 1H), 2.23 (d, J = 2.5 Hz,
6H), 2.16 (s, 3H). 13C NMR (151 MHz, CD3OD) δ 166.2, 165.5,
163.9, 92.6, 57.4, 54.7, 41.9, 23.3. HPLC-MS (basic mode): tR = 2.6
min, purity: >99%, [M + H]+: 208. HR-MS [M + H]+ calcd for
C10H18N5
+: 208.1557, found 208.1550.
4-(3-Aminoazetidin-1-yl)pyrimidin-2-amine Fumarate (14a). To
a solution of carbamate 24a (433 mg, 1.63 mmol) in MeOH (25 mL)
was added aq HCl (37%, 0.74 mL, 8.94 mmol). The reaction mixture
was stirred at rt overnight. The solvents were removed under reduced
pressure. The residue was dissolved in DCM/MeOH (4:1, 25 mL).
The pH was adjusted to above 10 with NH3 solution (7 N) in MeOH.
The suspension was filtered. The solvents were removed under
reduced pressure. The free base (248 mg, 1.50 mmol) was dissolved
in MeOH (4 mL), and fumaric acid (88 mg, 0.75 mmol) in MeOH (1
mL) was added. The clear solution was concentrated until a
suspension formed. The suspension was cooled overnight at 5 °C.
The formed solid was collected by filtration, washed, and dried in
vacuo. Dissolving in H2O (5 mL) and freeze-drying gave the title
compound as a white fluffy solid (134 mg, 37%). The base-to-fumaric-
acid ratio was 1:0.5 based on the 1H NMR peak integration. mp:
222.7−224.1 °C. 1H NMR (600 MHz, CD3OD/D2O) δ 7.62 (d, J =
7.3 Hz, 1H), 6.45 (s, 1H), 6.01 (d, J = 7.3 Hz, 1H), 4.57 (br, 2H),
4.38−4.15 (m, 3H). 13C NMR (151 MHz, CD3OD/D2O) δ 174.7,
162.9, 155.8, 142.4, 136.3, 95.8, 55.4, 54.9, 41.7. HPLC-MS (basic
mode): tR = 1.7 min, purity: 96.1%, [M + H]
+: 166. HR-MS [M +
H]+ calcd for C7H12N5
+: 166.1087, found 166.1082.
4-(3-(Methylamino)azetidin-1-yl)pyrimidin-2-amine Fumarate
(14b). To a solution of carbamate 24b (501 mg, 1.79 mmol) in
MeOH (8 mL) was added aq HCl (37%, 0.54 mL, 6.52 mmol). The
reaction mixture was stirred at rt overnight. The solvents were
removed under reduced pressure. The residue was dissolved in DCM/
MeOH (9:1, 25 mL). The pH was adjusted to above 10 with NH3
solution (7 N) in MeOH. The suspension was filtered. The solvents
were removed under reduced pressure. The crude free base (205 mg,
1.13 mmol) was dissolved in MeOH (25 mL), and fumaric acid (131
mg, 1.13 mmol) in MeOH (10 mL) was added. The clear solution
was concentrated until a suspension formed. The suspension was
cooled for 1 h at 5 °C. The formed solid was collected by filtration,
washed, and dried in vacuo. Dissolving in H2O (5 mL) and freeze-
drying gave the title compound as a white fluffy solid (250 mg, 53%).
The base-to-fumaric-acid ratio was 1:0.7 based on the 1H NMR peak
integration. mp: 230.1−230.5 °C. 1H NMR (600 MHz, CD3OD/
D2O) δ 7.64 (d, J = 7.0 Hz, 1H), 6.43 (s, 1H), 5.96 (d, J = 7.1 Hz,
1H), 4.46 (dd, J = 11.1, 7.6 Hz, 2H), 4.18 (dd, J = 11.2, 4.5 Hz, 2H),
4.13−4.06 (m, 1H), 2.62 (s, 3H). 13C NMR (151 MHz, CD3OD/
D2O) δ 175.2, 163.3, 157.7, 146.0, 136.5, 95.5, 54.5, 49.5, 31.8.
HPLC-MS (basic mode): tR = 2.1 min, purity: 95.6%, [M + H]
+: 180.
HR-MS [M + H]+ calcd for C8H14N5
+: 180.1244, found 180.1238.
4-(3-(Ethylamino)azetidin-1-yl)pyrimidin-2-amine Fumarate
(14c). To a solution of carbamate 24c (117 mg, 0.40 mmol) in
MeOH (4 mL) was added aq HCl (37%, 0.30 mL, 3.62 mmol). The
reaction mixture was stirred at rt overnight. The solvents were
removed under reduced pressure. The residue was dissolved in DCM/
MeOH (9:1, 4 mL). The pH was adjusted to above 10 with NH3
solution (7 N) in MeOH. The suspension was filtered. The solvents
were removed under reduced pressure. The crude free base (54 mg,
0.28 mmol) was dissolved in MeOH (8 mL), and fumaric acid (32
mg, 0.28 mmol) in MeOH (3 mL) was added. After partial
evaporation of MeOH and addition of EtOAc (3 mL), a precipitate
was formed. The suspension was cooled for 3 h at 5 °C. The formed
solid was collected by filtration, washed, and dried in vacuo.
Dissolving in H2O (5 mL) and freeze-drying gave the title compound
as a white fluffy solid (18 mg, 17%). The base-to-fumaric-acid ratio
was 1:0.6 based on the 1H NMR peak integration. mp: 206.8−208.5
°C. 1H NMR (600 MHz, CD3OD/D2O) δ 7.76 (d, J = 7.3 Hz, 1H),
6.70 (s, 1H), 6.16 (d, J = 7.3 Hz, 1H), 4.68 (br, 2H), 4.55−4.31 (m,
3H), 3.19 (q, J = 7.3 Hz, 2H), 1.41 (t, J = 7.3 Hz, 3H). 13C NMR
(151 MHz, CD3OD/D2O) δ 171.9, 163.2, 156.0, 142.7, 136.0, 95.7,
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54.5, 54.1, 47.7, 42.3, 11.6. HPLC-MS (basic mode): tR = 2.2 min,
purity: 91.8%, [M + H]+: 194. HR-MS [M + H]+ calcd for C9H16N5
+:
194.1400, found 194.1393.
4-(3-(Propylamino)azetidin-1-yl)pyrimidin-2-amine Fumarate
Hydrate (14d, VUF16839). To a solution of carbamate 24d (1.19 g,
3.87 mmol) in MeOH (20 mL) was added aq HCl (37%, 3.2 mL,
38.6 mmol). The reaction mixture was stirred at rt overnight and
subsequently at 50 °C for 30 min. The solvents were removed under
reduced pressure. The residue was dissolved in DCM/MeOH (4:1, 20
mL). The pH was adjusted to above 10 with NH3 solution (7 N) in
MeOH. The suspension was filtered. The solvents were removed
under reduced pressure. The crude free base (871 mg, 3.87 mmol)
was dissolved in MeOH (10 mL), and fumaric acid (453 mg, 3.90
mmol) in MeOH (10 mL) was added. The solvent was removed
under reduced pressure, and the residue was recrystallized from
EtOH. The suspension was cooled for 1 h at 5 °C. The crystals were
filtered, washed with EtOH, and dried in vacuo. Dissolving in H2O
(20 mL) and freeze-drying gave the title compound as a white fluffy
solid (803 mg, 58%). The base-to-fumaric-acid ratio was 1:1 based on
the 1H NMR peak integration. mp: 213.8−214.2 °C. 1H NMR (500
MHz, D2O) δ 7.61 (d, J = 7.3 Hz, 1H), 6.43 (s, 2H), 5.99 (d, J = 7.3
Hz, 1H), 4.56 (br, 2H), 4.40−4.19 (m, 3H), 3.06−2.92 (m, 2H), 1.68
(sext, J = 7.5 Hz, 2H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (151 MHz,
CD3OD/D2O) δ 175.2, 162.9, 155.8, 142.7, 136.3, 95.7, 54.4 53.9,
48.4, 47.9, 20.2, 11.1. HPLC-MS (basic mode): tR = 2.7 min, purity:
97.9%, [M + H]+: 208. HR-MS [M + H]+ calcd for C10H18N5
+:
208.1557, found 208.1566. Anal. calcd for C10H17N5·C4H4O4·
1.75H2O: C, 47.38; H, 6.96; N, 19.73; O, 25.92; Cl, 0.00. Found:
C, 47.07; H, 6.97; N, 19.43; O, 25.60; Cl, <0.1.
4-(3-(Isopropylamino)azetidin-1-yl)pyrimidin-2-amine Fuma-
rate (14e). To a solution of free base 14a (100 mg, 0.60 mmol) in
DCM (4 mL) and MeOH (1 mL) were added acetone (48 μL, 0.66
mmol) and AcOH (34 μL, 0.60 mmol). After 10 min of stirring at rt,
NaBH(OAc)3 (201 mg, 0.90 mmol) was added, and the resulting
mixture was stirred at rt overnight. The reaction mixture was
quenched with 5 M aq NaOH (two drops). The solvents were
removed under reduced pressure. The residue was purified by column
chromatography (DCM/MeOH/TEA 100:0:0−80:18:2). The se-
lected fractions were collected, and the solvents were removed under
reduced pressure. The residue was dissolved in DCM/MeOH (9:1, 10
mL) and washed with satd. aq Na2CO3 solution (10 mL). The
aqueous layer was extracted with DCM/MeOH (9:1, 2 × 5 mL). The
combined organic phases were dried over Na2SO4, filtered, and
concentrated in vacuo. The free base (32 mg, 0.154 mmol) was
dissolved in MeOH (1 mL), and fumaric acid (18 mg, 0.154 mmol) in
MeOH (1 mL) was added. After partial evaporation of MeOH and
addition of EtOAc (5 mL), a precipitate was formed. The suspension
was cooled for 1 h at 5 °C. The formed solid was collected by
filtration, washed, and dried in vacuo. Dissolving in H2O (5 mL) and
freeze-drying gave the title compound as a white fluffy solid (42 mg,
22%). The base-to-fumaric-acid ratio was 1:1 based on the 1H NMR
peak integration. mp: 219.0−219.3 °C. 1H NMR (500 MHz,
CD3OD/D2O) δ 7.76 (d, J = 7.1 Hz, 1H), 6.68−6.55 (m, 2H),
6.14−6.03 (m, 1H), 4.67−4.56 (m, 2H), 4.43−4.29 (m, 3H), 3.51−
3.39 (m, 1H), 1.43−1.34 (m, 6H). 13C NMR (151 MHz, CD3OD/
D2O) δ 174.2, 174.0, 163.4, 157.4, 157.1, 144.9, 144.5, 136.7, 95.5,
95.4, 55.3, 55.1, 50.9, 50.6, 46.2, 46.1, 20.0, 19.8 (multiple sets
observed). HPLC-MS (basic mode): tR = 2.7 min, purity: >99%, [M +
H]+: 208. HR-MS [M + H]+ calcd for C10H18N5
+: 208.1557, found
208.1566.
4-(3-(Butylamino)azetidin-1-yl)pyrimidin-2-amine Fumarate
(14f). To a solution of carbamate 24f (32 mg, 0.19 mmol) in
MeOH (3 mL) was added aq HCl (37%, 0.158 mL, 1.19 mmol). The
reaction mixture was stirred at rt overnight. The solvents were
removed under reduced pressure. The residue was dissolved in DCM/
MeOH (4:1, 5 mL). The pH was adjusted to above 10 with NH3
solution (7 N) in MeOH. The suspension was filtered. The solvents
were removed under reduced pressure. The free base (48 mg, 0.19
mmol) was dissolved in MeOH (1 mL), and fumaric acid (22 mg,
0.19 mmol) in MeOH (1 mL) was added. After partial evaporation of
MeOH and addition of EtOAc (5 mL), a precipitate formed. The
suspension was cooled for 1 h at 5 °C. The formed solid was collected
by filtration, washed, and dried in vacuo. The title compound was
obtained as a white solid (34 mg, 58%). The base-to-fumaric-acid
ratio was 1:0.75 based on the 1H NMR peak integration. mp: 169.6−
169.9 °C. 1H NMR (600 MHz, CD3OD/D2O) δ 7.72−7.66 (m, 1H),
6.66 (s, 1H), 6.06 (d, J = 7.2 Hz, 1H), 4.54 (br, 2H), 4.34 (br, 2H),
4.27−4.21 (m, 1H), 3.02−2.95 (m, 2H), 1.72−1.64 (m, 2H), 1.43
(sext, J = 7.4 Hz, 2H), 0.97 (t, J = 7.4 Hz, 3H). 13C NMR (151 MHz,
CD3OD/D2O) δ 170.0, 163.6, 156.7, 143.1, 135.8, 95.5, 54.7, 48.6,
47.0, 29.6, 20.9, 13.9. HPLC-MS (basic mode): tR = 3.1 min, purity:
94.6%, [M + H]+: 222. HR-MS [M + H]+ calcd for C11H20N5
+:
222.1713, found 222.1705.
(rac)-4-(3-(sec-Butylamino)azetidin-1-yl)pyrimidin-2-amine Fu-
marate (14g). To a solution of free base 14a (100 mg, 0.60
mmol) in DCM (4 mL) and MeOH (1 mL) were added butane-2-
one (64 μL, 0.66 mmol) and AcOH (34 μL, 0.60 mmol). After 10
min of stirring at rt, NaBH(OAc)3 (201 mg, 0.90 mmol) was added,
and the resulting mixture was stirred at rt overnight. The reaction
mixture was quenched with 5 M aq NaOH (two drops). The solvents
were removed under reduced pressure. The residue was purified by
column chromatography (DCM/MeOH/TEA 100:0:0−80:18:2).
The selected fractions were collected, and the solvents were removed
under reduced pressure. The residue was dissolved in DCM/MeOH
(9:1, 10 mL) and washed with satd. aq Na2CO3 solution (10 mL).
The aqueous layer was extracted with DCM/MeOH (9:1, 2 × 5 mL).
The combined organic phases were dried over Na2SO4, filtered, and
concentrated in vacuo. The free base (25 mg, 0.113 mmol) was
dissolved in MeOH (1 mL), and fumaric acid (13 mg, 0.113 mmol) in
MeOH (1 mL) was added. After partial evaporation of MeOH and
addition of EtOAc (5 mL), a precipitate formed. The suspension was
cooled for 1 h at 5 °C. The formed solid was collected by filtration,
washed, and dried in vacuo. Dissolving in H2O (5 mL) and freeze-
drying gave the title compound as a white fluffy solid (32 mg, 16%).
The base-to-fumaric-acid ratio was 1:1 based on the 1H NMR peak
integration. mp: 214.6−215.4 °C. 1H NMR (500 MHz, CD3OD/
D2O) δ 7.74 (d, J = 7.1 Hz, 1H), 6.64−6.53 (m, 2H), 6.12−6.05 (m,
1H), 4.62 (br, 2H), 4.47−4.30 (m, 3H), 3.28 (br, 1H), 1.90−1.80 (m,
1H), 1.69−1.57 (m, 1H), 1.38−1.30 (m, 3H), 1.05 (t, J = 7.5 Hz,
3H). 13C NMR (151 MHz, CD3OD/D2O) δ 174.5, 174.1, 163.2,
156.9, 156.8, 144.3, 143.8, 136.7, 95.6, 95.5, 56.1, 56.0, 55.0, 46.1,
46.0, 27.4, 27.2, 16.3, 16.2, 9.8 (multiple sets observed). HPLC-MS
(basic mode): tR = 3.0 min, purity: 95.6%, [M + H]
+: 222. HR-MS
[M + H]+ calcd for C11H20N5
+: 222.1713, found 222.1715.
4-(3-(Isobutylamino)azetidin-1-yl)pyrimidin-2-amine Fumarate
(14h). To a solution of free base 14a (100 mg, 0.60 mmol) in
DCM (4 mL) and MeOH (1 mL) were added isobutyraldehyde (66
μL, 0.66 mmol) and AcOH (34 μL, 0.60 mmol). After 10 min of
stirring at rt, NaBH(OAc)3 (201 mg, 0.90 mmol) was added, and the
resulting mixture was stirred at rt overnight. The reaction mixture was
quenched with 5 M aq NaOH (two drops). The solvents were
removed under reduced pressure. The residue was purified by column
chromatography (DCM/MeOH/TEA 100:0:0−80:18:2). The se-
lected fractions were collected, and the solvents were removed under
reduced pressure. The residue was dissolved in DCM/MeOH (9:1, 10
mL) and washed with satd. aq Na2CO3 solution (10 mL). The
aqueous layer was extracted with DCM/MeOH (9:1, 2 × 5 mL). The
combined organic phases were dried over Na2SO4, filtered, and
concentrated in vacuo. The free base (59 mg, 0.267 mmol) was
dissolved in MeOH (1 mL), and fumaric acid (31 mg, 0.267 mmol) in
MeOH (1 mL) was added. After partial evaporation of MeOH and
addition of EtOAc (5 mL), a precipitate formed. The suspension was
cooled for 1 h at 5 °C. The formed solid was collected by filtration,
washed, and dried in vacuo. Dissolving in H2O (5 mL) and freeze-
drying gave the title compound as a white fluffy solid (78 mg, 38%).
The base-to-fumaric-acid ratio was 1:1 based on the 1H NMR peak
integration. mp: 230.9−231.3 °C. 1H NMR (500 MHz, CD3OD/
D2O) δ 7.73 (d, J = 7.2 Hz, 1H), 6.59−6.55 (m, 2H), 6.09 (d, J = 7.2
Hz, 1H), 4.59 (t, J = 9.5 Hz, 2H), 4.37 (br app d, 2H), 4.30−4.23 (m,
1H), 2.88 (dd, J = 7.2, 3.6 Hz, 2H), 2.11−2.03 (m, 1H), 1.08 (d, J =
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6.7 Hz, 6H). 13C NMR (151 MHz, CD3ODD2O) δ 174.3, 174.2,
163.2, 156.7, 156.7, 143.7, 143.7, 136.6, 95.6, 95.5, 54.6, 54.0, 48.6,
27.3, 27.2, 20.3 (multiple sets observed). HPLC-MS (basic mode): tR
= 3.1 min, purity: >99%, [M + H]+: 222. HR-MS [M + H]+ calcd for
C11H20N5
+: 222.1713, found 222.1716.
4-(3-(Dimethylamino)azetidin-1-yl)pyrimidin-2-amine Fumarate
(14i). To a solution of amine fumarate 14b (100 mg, 0.34 mmol) in
MeOH (25 mL) were added formaline (37%, 70 μL, 0.94 mmol) and
AcOH (20 μL, 0.34 mmol). After 10 min of stirring at rt,
NaBH(OAc)3 (108 mg, 0.68 mmol) was added, and the resulting
mixture was stirred at rt overnight. The reaction mixture was
quenched with 5 M aq NaOH (two drops). The solvents were
removed under reduced pressure. The residue was purified by column
chromatography (DCM/MeOH/TEA 100:0:0−90:9:1). The selected
fractions were collected, and the solvents were removed under
reduced pressure. The residue was dissolved in DCM/MeOH (9:1, 20
mL). The pH was adjusted to above 10 with NH3 solution (7 N) in
MeOH. The suspension was filtered. The solvents were removed
under reduced pressure. The crude free base (25 mg, 0.130 mmol)
was dissolved in MeOH (5 mL), and fumaric acid (7.5 mg, 0.065
mmol) in MeOH (2.5 mL) was added. The solvent was evaporated
until a suspension formed. The suspension was cooled overnight at 5
°C. The formed solid was collected by filtration, washed, and dried in
vacuo. Dissolving in H2O (5 mL) and freeze-drying gave the title
compound as a white fluffy solid (31 mg, 36%). The base-to-fumaric-
acid ratio was 1:0.5 based on the 1H NMR peak integration. mp:
224.0−224.4 °C. 1H NMR (500 MHz, CD3OD/D2O) δ 7.66 (d, J =
7.0 Hz, 1H), 6.50 (s, 1H), 5.98 (d, J = 7.0 Hz, 1H), 4.35−4.27 (m,
2H), 4.08 (dd, J = 10.8, 4.9 Hz, 2H), 3.62−3.53 (m, 1H), 2.36 (s,
6H). 13C NMR (151 MHz, CD3OD/D2O) δ 175.0, 163.2, 157.8,
145.6, 136.7, 95.4, 56.4, 54.4, 41.5. HPLC-MS (basic mode): tR = 2.4
min, purity: >99%, [M + H]+: 194. HR-MS [M + H]+ calcd for
C9H16N5
+: 194.1400, found 194.1395.
4-(3-(Diethylamino)azetidin-1-yl)pyrimidin-2-amine Fumarate
(14j). To a solution of free base 14a (100 mg, 0.60 mmol) in
DCM (4 mL) and MeOH (1 mL) were added acetaldehyde (0.34
mL, 6 mmol) and AcOH (34 μL, 0.60 mmol). After 10 min of stirring
at rt, NaBH(OAc)3 (402 mg, 1.80 mmol) was added, and the
resulting mixture was stirred at rt overnight. The reaction mixture was
quenched with 5 M aq NaOH (two drops). The solvents were
removed under reduced pressure. The residue was purified by column
chromatography (DCM/MeOH/TEA 100:0:0−80:18:2). The se-
lected fractions were collected, and the solvents were removed under
reduced pressure. The residue was dissolved in DCM/MeOH (9:1, 10
mL) and washed with satd. aq Na2CO3 solution (10 mL). The
aqueous layer was extracted with DCM/MeOH (9:1, 2 × 5 mL). The
combined organic phases were dried over Na2SO4, filtered, and
concentrated in vacuo. The free base (82 mg, 0.37 mmol) was
dissolved in MeOH (1 mL), and fumaric acid (43 mg, 0.37 mmol) in
MeOH (1 mL) was added. After partial evaporation of MeOH and
addition of EtOAc (5 mL), a precipitate formed. The suspension was
cooled for 1 h at 5 °C. The formed solid was collected by filtration,
washed, and dried in vacuo. Dissolving in H2O (5 mL) and freeze-
drying gave the title compound as a white fluffy solid (90 mg, 44%).
The base-to-fumaric-acid ratio was 1:1 based on the 1H NMR peak
integration. mp: 229.6−229.8 °C. 1H NMR (600 MHz, CD3OD/
D2O) δ 7.74 (d, J = 7.1 Hz, 1H), 6.64−6.55 (m, 2H), 6.10 (dd, J =
7.2, 4.0 Hz, 1H), 4.62−4.51 (m, 2H), 4.50−4.41 (m, 2H), 4.41−4.29
(m, 1H), 3.28−3.13 (m, 4H), 1.40−1.27 (m, 6H). 13C NMR (151
MHz, CD3OD/D2O) δ 174.1, 173.8, 163.3, 157.0, 156.9, 144.1,
144.0, 136.6, 95.6, 95.5, 53.9, 52.7, 45.6, 45.4, 9.3, 9.2 (multiple sets
observed). HPLC-MS (basic mode): tR = 3.0 min, purity: 97.3%, [M
+ H]+: 222. HR-MS [M + H]+ calcd for C11H20N5
+: 222.1713, found
222.1722.
4-(3-(Pyrrolidin-1-yl)azetidin-1-yl)pyrimidin-2-amine Fumarate
(14k). To a solution of free base 14a (100 mg, 0.60 mmol) in
MeCN (20 mL) were added 1,4-diiodobutane (0.095 mL, 0.72
mmol) and K2CO3 (166 mg, 1.20 mmol). The resulting mixture was
heated at reflux for 16 h. The solvent was removed under reduced
pressure. The residue was purified by column chromatography
(DCM/MeOH/TEA 100:0:0−80:18:2). The selected fractions were
collected, and the solvents were removed under reduced pressure.
The residue was dissolved in DCM/MeOH (9:1, 10 mL) and washed
with satd. aq Na2CO3 solution (10 mL). The aqueous layer was
extracted with DCM/MeOH (9:1, 2 × 5 mL). The combined organic
phases were dried over Na2SO4, filtered, and concentrated in vacuo.
The free base (32 mg, 0.146 mmol) was dissolved in MeOH (1 mL),
and fumaric acid (17 mg, 0.146 mmol) in MeOH (1 mL) was added.
After partial evaporation of MeOH and addition of EtOAc (5 mL), a
precipitate formed. The suspension was cooled for 1 h at 5 °C. The
formed solid was collected by filtration, washed, and dried in vacuo.
Dissolving in H2O (5 mL) and freeze-drying gave the title compound
as a white fluffy solid (20 mg, 9%). The base-to-fumaric-acid ratio was
1:1.15 based on the 1H NMR peak integration. mp: 228.3−228.6 °C.
1H NMR (600 MHz, CD3OD/D2O) δ 7.74 (d, J = 7.2 Hz, 1H), 6.58
(s, 2H), 6.12 (d, J = 7.2 Hz, 1H), 4.63 (br, 2H), 4.46 (br, 2H), 4.39−
4.31 (m, 1H), 3.42 (br, 4H), 2.24−2.11 (m, 4H). 13C NMR (151
MHz, CD3OD/D2O) δ 173.8, 163.2, 156.3, 143.2, 136.4, 95.6, 54.6,
54.1, 53.3, 24.2. HPLC-MS (basic mode): tR = 2.8 min, purity: >99%,
[M + H]+: 220. HR-MS [M + H]+ calcd for C11H18N5
+: 220.1557,
found 220.1563.
4-Chloro-6-isopropylpyrimidin-2-amine (17). Pyrimidin-4(3H)-
one 15 (4.87 g, 31.8 mmol) was dissolved in POCl3 (40 mL, 0.43
mol). The mixture was heated to reflux for 3 h. The solvent was
removed under reduced pressure. Ice (150 g) was carefully added to
the residue. The pH of the mixture was adjusted to 9−10 with aq
NaOH (2.5 M). The mixture was extracted with DCM (3 × 100 mL).
The combined organic phases were dried over Na2SO4, filtered, and
concentrated in vacuo. Purification by flash chromatography (DCM/
MeOH 10:0−9:1) gave the title compound as an off-white solid (1.41
g, 26%). 1H NMR (500 MHz, CDCl3) δ 6.53 (s, 1H), 5.33 (br, 2H),
2.77 (hept, J = 6.9 Hz, 1H), 1.22 (d, J = 6.9 Hz, 6H). HPLC-MS
(acidic mode): tR = 3.5 min, purity: 96.8%, [M + H]
+: 172.
4-Chloro-6-ethylpyrimidin-2-amine (18). Pyrimidin-4(3H)-one
16 (6.13 g, 44.1 mmol) was dissolved in POCl3 (50 mL, 0.54 mol).
The mixture was heated to reflux for 3 h. The solvent was removed
under reduced pressure. Ice (150 g) was carefully added to the
residue. The pH of the mixture was adjusted to 9−10 with aq NaOH
(2.5 M). The mixture was extracted with DCM (3 × 10 mL). The
combined organic phases were dried over Na2SO4, filtered, and
concentrated in vacuo. Purification by flash chromatography (DCM/
MeOH 10:0−9:1) gave the title compound as an off-white solid (3.63
g, 52%). 1H (500 MHz, CDCl3) δ 6.53 (s, 1H), 5.43 (br, 2H), 2.57
(q, J = 7.6 Hz, 2H), 1.23 (t, J = 7.6 Hz, 3H). HPLC-MS (acidic
mode): tR = 3.0 min, purity: >99%, [M + H]
+: 158.
tert-Butyl (1-(2-Amino-6-isopropylpyrimidin-4-yl)azetidin-3-yl)-
carbamate (21a). A microwave vial charged with chloride 17 (400
g, 2.33 mmol), carbamate 28a (402 mg, 2.33 mmol), DIPEA (0.41
mL, 2.33 mmol), and dioxane (10 mL) was heated for 120 min at 150
°C under microwave irradiation. The reaction mixture was diluted
with water (20 mL) and extracted with DCM (3 × 20 mL). The
combined organic phases were dried over Na2SO4, filtered, and
concentrated in vacuo. Purification by flash chromatography (DCM/
MeOH/TEA 100:0:0−90:9:1) gave the title compound as a colorless
oil (351 mg, 49%). 1H NMR (300 MHz, CDCl3) δ 5.48 (s, 1H), 5.01
(br, 1H), 4.80 (br, 2H), 4.57 (br, 1H), 4.31 (t, J = 8.3 Hz, 2H), 3.89−
3.74 (m, 2H), 2.65 (hept, J = 6.9 Hz, 1H), 1.45 (s, 9H), 1.19 (d, J =
6.9 Hz, 6H). HPLC-MS (acidic mode): tR = 3.1 min, purity: >99%,
[M + H]+: 308.
tert-Butyl (1-(2-Amino-6-isopropylpyrimidin-4-yl)azetidin-3-yl)-
(methyl)carbamate (21b). A microwave vial charged with chloride
17 (300 mg, 1.75 mmol), carbamate hydrochloride 28b (389 mg, 1.75
mmol), DIPEA (0.61 mL, 3.50 mmol), and dioxane (10 mL) was
heated for 30 min at 150 °C under microwave irradiation. The
reaction mixture was diluted with water (20 mL) and extracted with
DCM (3 × 15 mL). The combined organic phases were dried over
Na2SO4, filtered, and concentrated in vacuo. Purification by flash
chromatography (DCM/MeOH 10:0−9:1) gave the title compound
as a yellow oil (280 mg, 50%). 1H NMR (250 MHz, CDCl3) δ 5.50
(s, 1H), 5.03 (br, 1H), 4.79 (br, 2H), 4.20 (t, J = 8.6 Hz, 2H), 4.07−
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3.95 (m, 2H), 2.93 (s, 3H), 2.65 (hept, J = 6.9 Hz, 1H), 1.46 (s, 9H),
1.20 (d, J = 6.9 Hz, 6H). HPLC-MS (acidic mode): tR = 3.4 min,
purity: >99%, [M + H]+: 322.
tert-Butyl (1-(2-Amino-6-isopropylpyrimidin-4-yl)azetidin-3-yl)-
(ethyl)carbamate (21c). Carbamate 27c (1.02 g, 2.78 mmol) was
dissolved in MeOH/EtOH (10:10 mL) and reacted with H2 gas
under atmospheric pressure using Pd/C (5%, 0.60 g) overnight at rt.
The mixture was filtered over Celite, and the filtrate was concentrated
in vacuo. The resulting yellowish oil (900 mg, a mixture of
intermediate and diphenylmethane) was used in the next step
without further purification. A microwave vial charged with chloride
17 (103 mg, 0.60 mmol), crude intermediate (221 mg), DIPEA
(0.105 mL, 0.60 mmol), and dioxane (5 mL) was heated for 90 min at
150 °C under microwave irradiation. The reaction mixture was
diluted with water (10 mL) and extracted with DCM (3 × 10 mL).
The combined organic phases were dried over Na2SO4, filtered, and
concentrated in vacuo. Purification by flash chromatography (DCM/
MeOH 10:0−9:1) gave the title compound as a yellowish oil (79 mg,
35% over two steps, extrapolated). 1H NMR (300 MHz, CDCl3) δ
6.03 (br, 2H), 5.46 (s, 1H), 5.06 (br, 1H), 4.73 (br, 1H), 4.25 (t, J =
8.7 Hz, 2H), 4.17−4.05 (m, 2H), 3.33 (q, J = 7.0 Hz, 2H), 2.76 (hept,
J = 6.9 Hz, 1H), 1.46 (s, 9H), 1.23 (d, J = 6.9 Hz, 6H), 1.14 (t, J = 7.0
Hz, 3H). HPLC-MS (acidic mode): tR = 3.6 min, purity: >99%, [M +
H]+: 336.
tert-Butyl (1-(2-Amino-6-ethylpyrimidin-4-yl)azetidin-3-yl)-
carbamate (22a). A microwave vial charged with chloride 18 (500
mg, 3.17 mmol), carbamate 28a (546 mg, 3.17 mmol), DIPEA (0.55
mL, 3.17 mmol), and dioxane (11 mL) was heated for 45 min at 150
°C under microwave irradiation. The reaction mixture was diluted
with water (50 mL) and extracted with DCM (3 × 50 mL). The
combined organic phases were dried over Na2SO4, filtered, and
concentrated in vacuo. Purification by flash chromatography (DCM/
MeOH 10:0−9:1) gave the title compound as a colorless oil (250 mg,
27%). 1H NMR (300 MHz, CDCl3) δ 5.49 (s, 1H), 4.99 (br, 1H),
4.78 (br, 2H), 4.58 (br, 1H), 4.31 (t, J = 8.3 Hz, 2H), 3.85−3.73 (m,
2H), 2.46 (q, J = 7.6 Hz, 2H), 1.45 (s, 9H), 1.20 (t, J = 7.6 Hz, 3H).
HPLC-MS (acidic mode): tR = 3.0 min, purity: 94.5%, [M + H]
+:
294.
tert-Butyl (1-(2-Amino-6-ethylpyrimidin-4-yl)azetidin-3-yl)-
(methyl)carbamate (22b). A microwave vial charged with chloride
18 (500 mg, 3.17 mmol), carbamate hydrochloride 28b (707 mg, 3.17
mmol), DIPEA (1.11 mL, 6.35 mmol), and dioxane (11 mL) was
heated for 45 min at 150 °C under microwave irradiation. The
reaction mixture was diluted with water (15 mL) and extracted with
DCM (3 × 10 mL). The combined organic phases were dried over
Na2SO4, filtered, and concentrated in vacuo. Purification by flash
chromatography (DCM/MeOH 10:0−9:1) gave the title compound
as a colorless oil (450 mg, 46%). 1H NMR (300 MHz, CDCl3) δ 5.52
(s, 1H), 5.00 (br, 1H), 4.77 (br, 2H), 4.20 (t, J = 8.6 Hz, 2H), 4.07−
3.94 (m, 2H), 2.92 (s, 3H), 2.47 (q, J = 7.6 Hz, 2H), 1.46 (s, 9H),
1.20 (t, J = 7.6 Hz, 3H). HPLC-MS (acidic mode): tR = 3.1 min,
purity: >99%, [M + H]+: 308.
tert-Butyl (1-(2-Amino-6-ethylpyrimidin-4-yl)azetidin-3-yl)-
(ethyl)carbamate (22c). Carbamate 27c (1.02 g, 2.78 mmol) was
dissolved in MeOH/EtOH (10:10 mL) and reacted with H2 gas
under atmospheric pressure using Pd/C (5%, 0.60 g) overnight at rt.
The mixture was filtered over Celite, and the filtrate was concentrated
in vacuo. The resulting yellowish oil (900 mg, a mixture of
intermediate and diphenylmethane) was used in the next step
without further purification. A microwave vial charged with chloride
18 (95 mg, 0.60 mmol), crude intermediate (221 mg), DIPEA (0.105
mL, 0.60 mmol), and dioxane (5 mL) was heated for 90 min at 150
°C under microwave irradiation. The reaction mixture was diluted
with water (10 mL) and extracted with DCM (3 × 10 mL). The
combined organic phases were dried over Na2SO4, filtered, and
concentrated in vacuo. Purification by flash chromatography (DCM/
MeOH 10:0−9:1) gave the title compound as a yellowish oil (92 mg,
42% over two steps, extrapolated). 1H NMR (300 MHz, CDCl3) δ
5.54 (s, 1H), 4.83 (br, 3H), 4.24 (t, J = 8.5 Hz, 2H), 4.12−3.96 (m,
2H), 3.36 (q, J = 7.1 Hz, 2H), 2.49 (q, J = 7.6 Hz, 2H), 1.48 (s, 9H),
1.29−1.11 (m, 6H). HPLC-MS (acidic mode): tR = 3.3 min, purity:
>99% %, [M + H]+: 322.
tert-Butyl (1-(2-Amino-6-methylpyrimidin-4-yl)azetidin-3-yl)-
carbamate (23a). A microwave vial charged with chloride 19 (1.00
g, 6.97 mmol), carbamate 28a (1.20 g, 6.97 mmol), DIPEA (1.22 mL,
6.99 mmol), and dioxane (20 mL) was heated for 60 min at 150 °C
under microwave irradiation. The reaction mixture was diluted with
water (40 mL) and extracted with DCM (3 × 40 mL). The combined
organic phases were dried over Na2SO4, filtered, and concentrated in
vacuo. Purification by flash chromatography (DCM/MeOH 10:0−
9:1) gave the title compound as a yellowish solid (726 mg, 36%). 1H
NMR (300 MHz, CDCl3) δ 5.50 (s, 1H), 4.99 (br, 1H), 4.78 (br,
2H), 4.58 (br, 1H), 4.30 (t, J = 8.3 Hz, 2H), 3.83−3.73 (m, 2H), 2.20
(s, 3H), 1.45 (s, 9H). HPLC-MS (acidic mode): tR = 2.7 min, purity:
95.5%, [M + H]+: 280.
tert-Butyl (1-(2-Amino-6-methylpyrimidin-4-yl)azetidin-3-yl)-
(methyl)carbamate (23b). A microwave vial charged with chloride
19 (287 mg, 2.00 mmol), carbamate hydrochloride 28b (445 mg, 2.00
mmol), DIPEA (0.70 mL, 4.00 mmol), and dioxane (4 mL) was
heated for 60 min at 150 °C under microwave irradiation. The
reaction mixture was diluted with water (15 mL) and extracted with
DCM (3 × 10 mL). The combined organic phases were dried over
Na2SO4, filtered, and concentrated in vacuo. Purification by flash
chromatography (DCM/MeOH 100:0−92:8) gave the title com-
pound as a colorless oil (501 mg, 46%). 1H NMR (300 MHz, CDCl3)
δ 5.51 (s, 1H), 4.99 (br, 1H), 4.81 (br, 2H), 4.19 (t, J = 8.6 Hz, 2H),
4.06−3.93 (m, 2H), 2.91 (s, 3H), 2.19 (s, 3H), 1.46 (s, 9H). HPLC-
MS (acidic mode): tR = 2.9 min, purity: 95.9%, [M + H]
+: 294.
tert-Butyl (1-(2-Amino-6-methylpyrimidin-4-yl)azetidin-3-yl)-
(ethyl)carbamate (23c). Carbamate 27c (1.02 g, 2.78 mmol) was
dissolved in MeOH/EtOH (10:10 mL) and reacted with H2 gas
under atmospheric pressure using Pd/C (5%, 0.60 g) overnight at rt.
The mixture was filtered over Celite, and the filtrate was concentrated
in vacuo. The resulting yellowish oil (900 mg, a mixture of
intermediate and diphenylmethane) was used in the next step
without further purification. A microwave vial charged with chloride
19 (101 mg, 0.71 mmol), crude intermediate (260 mg), DIPEA
(0.123 mL, 0.71 mmol), and dioxane (3 mL) was heated for 90 min at
150 °C under microwave irradiation. The reaction mixture was
diluted with water (10 mL) and extracted with DCM (3 × 10 mL).
The combined organic phases were dried over Na2SO4, filtered, and
concentrated in vacuo. Purification by flash chromatography (DCM/
MeOH 10:0−9:1) gave the title compound as a colorless oil (125 mg,
56% over two steps, extrapolated). 1H NMR (300 MHz, CDCl3) δ
5.52 (s, 1H), 4.75 (br, 3H), 4.20 (t, J = 8.5 Hz, 2H), 4.07−3.95 (m,
2H), 3.33 (q, J = 7.0 Hz, 2H), 2.20 (s, 3H), 1.46 (s, 9H), 1.15 (t, J =
7.0 Hz, 3H). HPLC-MS (acidic mode): tR = 3.2 min, purity: >99% %,
[M + H]+: 308.
tert-Butyl (1-(2-Aminopyrimidin-4-yl)azetidin-3-yl)carbamate
(24a). A microwave vial charged with chloride 20 (500 mg, 3.86
mmol), carbamate 28a (665 mg, 3.86 mmol), DIPEA (0.67 mL, 3.86
mmol), and dioxane (10 mL) was heated for 60 min at 150 °C under
microwave irradiation. The reaction mixture was diluted with water
(40 mL) and extracted with DCM (3 × 40 mL). The combined
organic phases were dried over Na2SO4, filtered, and concentrated in
vacuo. Purification by flash chromatography (DCM/MeOH 100:0−
88:12) gave the title compound as a colorless oil (434 mg, 39%). 1H
NMR (300 MHz, CDCl3) δ 7.83 (d, J = 5.8 Hz, 1H), 5.61 (d, J = 5.8
Hz, 1H), 5.10 (br, 1H), 4.82 (s, 2H), 4.58 (br, 1H), 4.31 (t, J = 8.4
Hz, 2H), 3.86−3.74 (m, 2H), 1.45 (s, 9H). HPLC-MS (acidic mode):
tR = 2.6 min, purity: 91.6%, [M + H]
+: 266.
tert-Butyl (1-(2-Aminopyrimidin-4-yl)azetidin-3-yl)(methyl)-
carbamate (24b). A microwave vial charged with chloride 20 (500
mg, 3.86 mmol), carbamate hydrochloride 28b (723 mg, 3.86 mmol),
DIPEA (1.35 mL, 7.72 mmol), and dioxane (10 mL) was heated for
30 min at 150 °C under microwave irradiation. The reaction mixture
was diluted with water (40 mL) and extracted with DCM (3 × 40
mL). The combined organic phases were dried over Na2SO4, filtered,
and concentrated in vacuo. Purification by flash chromatography
(DCM/MeOH 100:0−88:12) gave the title compound as a colorless
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oil (501 mg, 46%). 1H NMR (300 MHz, CDCl3) δ 7.84 (d, J = 5.9
Hz, 1H), 5.65 (d, J = 5.9 Hz, 1H), 5.21−4.59 (m, 3H), 4.22 (t, J = 8.7
Hz, 2H), 4.09−3.98 (m, 2H), 2.93 (s, 3H), 1.47 (s, 9H). HPLC-MS
(acidic mode): tR = 2.8 min, purity: >99%, [M + H]
+: 280.
tert-Butyl (1-(2-Aminopyrimidin-4-yl)azetidin-3-yl)(ethyl)-
carbamate (24c). Carbamate 27c (1.02 g, 2.78 mmol) was dissolved
in MeOH/EtOH (10:10 mL) and reacted with H2 gas under
atmospheric pressure using Pd/C (5%, 0.60 g) overnight at rt. The
mixture was filtered through Celite. The Celite cake was washed with
MeOH (2 × 5 mL), and the combined filtrates were concentrated in
vacuo. The resulting yellowish oil (900 mg, a mixture of intermediate
and diphenylmethane) was used in the next step without further
purification. A microwave vial charged with chloride 20 (78 mg, 0.60
mmol), crude intermediate (221 mg), DIPEA (0.105 mL, 0.60
mmol), and dioxane (5 mL) was heated for 90 min at 150 °C under
microwave irradiation. The reaction mixture was diluted with water
(10 mL) and extracted with DCM (3 × 10 mL). The combined
organic phases were dried over Na2SO4, filtered, and concentrated in
vacuo. Purification by flash chromatography (DCM/MeOH 10:0−
9:1) gave the title compound as a colorless oil (117 mg, 50% over two
steps, extrapolated). 1H NMR (300 MHz, CDCl3) δ 7.84 (d, J = 5.8
Hz, 1H), 5.64 (d, J = 5.8 Hz, 1H), 4.77 (br, 3H), 4.22 (t, J = 8.5 Hz,
2H), 4.10−3.97 (m, 2H), 3.33 (q, J = 7.0 Hz, 2H), 1.45 (s, 9H), 1.15
(t, J = 7.0 Hz, 3H). HPLC-MS (acidic mode): tR = 3.0 min, purity:
95.5%, [M + H]+: 294.
tert-Butyl (1-(2-Aminopyrimidin-4-yl)azetidin-3-yl)(propyl)-
carbamate (24d). Carbamate 27d (2.09 g, 5.49 mmol) in MeOH
(100 mL) was passed through an H-cube fitted with a Pd/C (10%)
catalyst cartridge at a flow rate of 1 mL/min at 60 °C and at 10 atm
H2 pressure. The solvent was removed in vacuo. The resulting
colorless oil (2.03 g, a mixture of intermediate and diphenylmethane)
was used in the next step without further purification. A microwave
vial charged with chloride 20 (687 mg, 5.31 mmol), crude
intermediate (2.03 g), DIPEA (0.93 mL, 5.27 mmol), and NMP (5
mL) was heated for 30 min at 120 °C under microwave irradiation.
The mixture was purified by flash chromatography (DCM/MeOH/
TEA 100:0:0−90:9:1). The selected fractions were collected, and the
solvents were removed under reduced pressure. The residue was
dissolved in DCM (50 mL) and washed with satd. aq Na2CO3 (80
mL). The aqueous phase was extracted with DCM (2 × 50 mL). The
combined organic phases were dried over Na2SO4, filtered, and
concentrated in vacuo. The title compound was obtained as a
colorless oil (1.19 g, 71% over two steps). 1H NMR (500 MHz,
CDCl3) δ 7.83 (d, J = 5.8 Hz, 1H), 5.64 (d, J = 5.8 Hz, 1H), 5.06−
4.38 (m, 3H), 4.20 (t, J = 8.5 Hz, 2H), 4.07 (t, J = 7.6 Hz, 2H), 3.22
(t, J = 7.6 Hz, 2H), 1.54 (sext, J = 7.4 Hz, 2H), 1.44 (s, 9H), 0.88 (t, J
= 7.4 Hz, 3H). HPLC-MS (acidic mode): tR = 3.3 min, purity: >99%,
[M + H]+: 308.
tert-Butyl (1-(2-Aminopyrimidin-4-yl)azetidin-3-yl)(butyl)-
carbamate (24f). A solution of carbamate 27f (178 mg, 0.45
mmol) in MeOH (16 mL) was passed through an H-cube fitted with
a Pd/C (10%) catalyst cartridge at a flow rate of 1 mL/min at 60 °C
and at 10 atm H2 pressure. The solvent was removed in vacuo. The
resulting colorless oil (136 mg, a mixture of intermediate and
diphenylmethane) was used in the next step without further
purification. A microwave vial charged with chloride 20 (44 mg,
0.34 mmol), crude intermediate (136 mg), DIPEA (0.060 mL, 0.34
mmol), and NMP (0.5 mL) was heated for 30 min at 120 °C under
microwave irradiation. The mixture was purified by flash chromatog-
raphy (DCM/MeOH/TEA 100:0:0−80:18:2). The title compound
was obtained as an off-white solid (62 mg, 46% over two steps). 1H
NMR (300 MHz, CD3OD) δ 7.71 (d, J = 6.2 Hz, 1H), 5.77 (d, J = 6.0
Hz, 1H), 4.54 (s, 1H), 4.32−4.14 (m, 4H), 3.35−3.25 (m, 2H),
1.62−1.47 (m, 2H), 1.44 (s, 9H), 1.38−1.24 (m, 2H), 0.98−0.90 (m,
3H). HPLC-MS (acidic mode): tR = 3.4 min, purity: 97.5%, [M +
H]+: 322.
tert-Butyl (1-Benzhydrylazetidin-3-yl)carbamate (26). To a
solution of amine 25 (5.00 g, 21.0 mmol) in THF (40 mL) at 0
°C was added a solution of di-tert-butyl dicarbonate (5.40, 25.2
mmol) in THF (40 mL) and TEA (3.51 mL, 25.2 mmol). The
reaction mixture was warmed to rt and stirred for 2 h. The solvent was
evaporated. Purification by flash chromatography (c-hexane/EtOAc/
TEA 100:0:0−0:95:5) gave the title compound as a white solid (4.45
g, 63%). 1H NMR (300 MHz, CDCl3) δ 7.39 (d, J = 7.6 Hz, 4H),
7.32−7.22 (m, 4H), 7.22−7.12 (m, 2H), 4.87 (br, 1H), 4.30 (br, 2H),
3.53 (t, J = 6.3 Hz, 2H), 2.82 (br, 2H), 1.42 (s, 9H). HPLC-MS
(acidic mode): tR = 3.5 min, purity: 97.5%, [M + H]
+: 339.
tert-Butyl (1-Benzhydrylazetidin-3-yl)(ethyl)carbamate (27c). To
a solution of carbamate 26 (3.10 g, 9.2 mmol) in THF (30 mL) at 0
°C, NaH (60%, 0.44 g, 11.0 mmol) was added. When the evolution of
H2 gas subsided, iodoethane (0.81 mL, 10.1 mmol) was added
dropwise to the reaction mixture. The resulting mixture was stirred
overnight at rt. The reaction mixture was diluted with water (60 mL)
and extracted with DCM (3 × 40 mL). The combined organic phases
were dried over Na2SO4, filtered, and concentrated in vacuo.
Purification by flash chromatography (c-hexane/EtOAc 10:0−7:3)
gave the title compound as a white solid (1.95 g, 58%). 1H NMR (300
MHz, CDCl3) δ 7.48−7.35 (m, 4H), 7.32−7.23 (m, 4H), 7.23−7.12
(m, 2H), 4.34 (br, 2H), 3.51 (br, 2H), 3.27 (q, J = 7.1 Hz, 2H), 2.95
(br, 2H), 1.42 (s, 9H), 1.05 (t, J = 7.0 Hz, 3H). HPLC-MS (acidic
mode): tR = 3.9 min, purity: 99.6%, [M + H]
+: 367.
tert-Butyl (1-Benzhydrylazetidin-3-yl)(propyl)carbamate (27d).
To a solution of carbamate 26 (4.55 g, 13.2 mmol) in THF (30 mL)
at 0 °C, NaH (95%, 0.40 g, 10.5 mmol) was added. When the
evolution of H2 gas subsided, iodopropane (1.44 mL, 14.7 mmol) was
added dropwise to the reaction mixture. The resulting mixture was
stirred overnight at rt. The reaction mixture was diluted with water
(200 mL) and extracted with DCM (3 × 120 mL). The combined
organic phases were dried over Na2SO4, filtered, and concentrated in
vacuo. Purification by flash chromatography (c-hexane/EtOAc/TEA
100:0:0−70:28.5:1.5) gave the title compound as a white solid (2.09
g, 42%). 1H NMR (300 MHz, CDCl3) δ 7.46−7.35 (m, 4H), 7.33−
7.23 (m, 4H), 7.23−7.14 (m, 2H), 4.33 (s, 2H), 3.50 (t, J = 7.2 Hz,
2H), 3.22−3.10 (m, 2H), 2.93 (t, J = 6.9 Hz, 2H), 1.51−1.36 (m,
11H), 0.85 (t, J = 7.4 Hz, 3H). HPLC-MS (acidic mode): tR = 3.9
min, purity: 99.3%, [M + H]+: 381.
tert-Butyl (1-Benzhydrylazetidin-3-yl)(butyl)carbamate (27f). To
a solution of carbamate 26 (552 mg, 1.60 mmol) in THF (50 mL) at
0 °C, NaH (60%, 77 mg, 1.92 mmol) was added. When the evolution
of H2 gas subsided, iodobutane (0.20 mL, 1.76 mmol) was added
dropwise to the reaction mixture. The resulting mixture was stirred
overnight at rt. The reaction mixture was diluted with water (20 mL)
and extracted with DCM (3 × 15 mL). The combined organic phases
were dried over Na2SO4, filtered, and concentrated in vacuo.
Purification by flash chromatography (c-hexane/EtOAc/TEA
100:0:0−0:95:5) gave the title compound as a white solid (178 mg,
28%). 1H NMR (300 MHz, CDCl3) δ 7.46−7.36 (m, 4H), 7.32−7.23
(m, 4H), 7.23−7.14 (m, 2H), 4.33 (br, 2H), 3.59−3.35 (m, 2H),
3.26−3.12 (m, 2H), 2.93 (br, 2H), 1.50−1.34 (m, 11H, overlaps with
residual c-hexane), 1.33−1.17 (m, 2H), 0.90 (t, J = 7.2 Hz, 3H).
HPLC-MS (acidic mode): tR = 4.4 min, purity: 97.8%, [M + H]
+:
395.
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Gab́or Waǵner: 0000-0001-5111-6749
Marta Arimont: 0000-0002-9367-5298
Henry F. Vischer: 0000-0002-0184-6337
Maikel Wijtmans: 0000-0001-8955-8016
Rob Leurs: 0000-0003-1354-2848
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
Irma Hoekstra, Jasmina Elsayed, Mohamed Ibrahim, and Alex
de Waal are acknowledged for their assistance in synthesis. We
thank Hans Custers for HRMS measurements, Niels Hauwert
for nephelometry measurements, Inna Slynko for her
contribution to docking studies, and Jasper W. van de Sande
for pharmacological support. Profs. Beatrice Passani and
Patrizio Blandina are thanked for their discussions on the in
vivo work. This work was supported by The Netherlands
Organization for Scientific Research (NWO) TOPPUNT [“7
ways to 7TMR modulation (7-to-7)”] [Grant 718.014.002].
G.P. was supported by the Brazilian National Council for
Scientific and Technological Development fellowship (CNPq;
201511/2014-2). The contribution of Prof. Katarzyna Kiec-́
Kononowicz and Dr. Gniewomir Latacz was financially
supported by the Jagiellonian University Medical College,
Poland Grant no. N42/DBS/000039.
■ ABBREVIATIONS
α, intrinsic activity compared to histamine; cAMP, cyclic
adenosine monophosphate; CRE, cAMP response element;
DCM, dichloromethane; DIPEA, N,N-diisopropylethylamine;
FLIPR, fluorometric imaging plate reader; GPCR, G protein-
coupled receptor; GTPγS, guanosine 5′-O-[γ-thio]-
triphosphate; IFP, interaction fingerprint; i.p., intraperitoneal;
mp, melting point; MD, molecular dynamics; NAMH, N-α-
methylhistamine; NMP, N-methyl-2-pyrrolidone; SAR, struc-
ture−activity relationship; satd. aq, saturated aqueous; S.D.,
standard deviation; S.E.M., standard error of mean; SFR,
structure−function relationship; rt, room temperature; TEA,
triethylamine; THF, tetrahydrofuran; μW, microwave reaction
■ REFERENCES
(1) Panula, P.; Chazot, P. L.; Cowart, M.; Gutzmer, R.; Leurs, R.;
Liu, W. L. S.; Stark, H.; Thurmond, R. L.; Haas, H. L. International
Union of Basic and <tep-common:author-query>AQ9: Please check
whether the updated information in ref 1 is correct.</tep-
common:author-query>Clinical Pharmacology. XCVIII. Histamine
receptors. Pharmacol. Rev. 2014, 67, 601−655.
(2) Arrang, J. M.; Garbarg, M.; Schwartz, J. C. Auto-inhibition of
brain histamine release mediated by a novel class (H3) of histamine
receptor. Nature 1983, 302, 832−837.
(3) Schlicker, E.; Kathmann, M. Role of the histamine H3 receptor in
the central nervous system. Handb. Exp. Pharmacol. 2017, 241, 277−
299.
(4) Stark, H.; Kathmann, M.; Schlicker, E.; Schunack, W.; Schlegel,
B.; Sippl, W. Medicinal chemical and pharmacological aspects of
imidazole-containing histamine H3 receptor antagonists. Mini-Rev.
Med. Chem. 2004, 4, 965−977.
(5) Ganellin, C. R.; Leurquin, F.; Piripitsi, A.; Arrang, J. M.; Garbarg,
M.; Ligneau, X.; Schunack, W.; Schwartz, J.-C. Synthesis of potent
non-imidazole histamine H3-receptor antagonists. Arch. Pharm. 1998,
331, 395−404.
(6) Celanire, S.; Wijtmans, M.; Talaga, P.; Leurs, R.; de Esch, I. J. P.
Keynote review: Histamine H3 receptor antagonists reach out for the
clinic. Drug Discovery Today 2005, 10, 1613−1627.
(7) Lebois, E. P.; Jones, C. K.; Lindsley, C. W. The evolution of
histamine H3 antagonists/inverse agonists. Curr. Top. Med. Chem.
2011, 11, 648−660.
(8) Kuhne, S.; Wijtmans, M.; Lim, H. D.; Leurs, R.; de Esch, I. J. P.
Several down, a few to go: histamine H3 receptor ligands making the
final push towards the market? Expert Opin. Invest. Drugs 2011, 20,
1629−1648.
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(69) Korb, O.; Stützle, T.; Exner, T. E. An ant colony optimization
approach to flexible protein−ligand docking. Swarm Intell. 2007, 1,
115−134.
(70) Marcou, G.; Rognan, D. Optimizing fragment and scaffold
docking by use of molecular interaction fingerprints. J. Chem. Inf.
Model. 2007, 47, 195−207.
(71) de Graaf, C.; Kooistra, A. J.; Vischer, H. F.; Katritch, V.; Kuijer,
M.; Shiroishi, M.; Iwata, S.; Shimamura, T.; Stevens, R. C.; de Esch, I.
J. P.; Leurs, R. Crystal structure-based virtual screening for fragment-
like ligands of the human histamine H1 receptor. J. Med. Chem. 2011,
54, 8195−8206.
(72) Jakalian, A.; Jack, D. B.; Bayly, C. I. Fast, efficient generation of
high-quality atomic charges. AM1-BCC model: II. Parameterization
and validation. J. Comput. Chem. 2002, 23, 1623−1641.
(73) Berendsen, H. J. C.; van der Spoel, D.; van Drunen, R.
GROMACS: A message-passing parallel molecular dynamics
implementation. Comput. Phys. Commun. 1995, 91, 43−56.
(74) Cordomí, A.; Caltabiano, G.; Pardo, L. Membrane protein
simulations using AMBER force field and Berger lipid parameters. J.
Chem. Theory Comput. 2012, 8, 948−958.
(75) Roessler, W. G.; Brewer, C. R. Permanent turbidity standards.
Appl. Microbiol. 1967, 15, 1114−1121.
(76) Baell, J. B.; Holloway, G. A. New substructure filters for
removal of pan assay interference compounds (PAINS) from
screening libraries and for their exclusion in bioassays. J. Med.
Chem. 2010, 53, 2719−2740.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.9b01462
J. Med. Chem. 2019, 62, 10848−10866
10866
